AU2006231451A1 - Use of spirostenols to treat mitochondrial disorders - Google Patents
Use of spirostenols to treat mitochondrial disorders Download PDFInfo
- Publication number
- AU2006231451A1 AU2006231451A1 AU2006231451A AU2006231451A AU2006231451A1 AU 2006231451 A1 AU2006231451 A1 AU 2006231451A1 AU 2006231451 A AU2006231451 A AU 2006231451A AU 2006231451 A AU2006231451 A AU 2006231451A AU 2006231451 A1 AU2006231451 A1 AU 2006231451A1
- Authority
- AU
- Australia
- Prior art keywords
- mitochondrial
- alkyl
- compound
- hydroxy
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000012268 mitochondrial disease Diseases 0.000 title claims description 39
- XEMAZQRIKQEVPH-NLXSHYKESA-N [(1R,2S,4S,6R,8S,9S,12S,13S)-5',9,13-trimethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-7-ylidene]methanol Chemical class O1CC(C)CC[C@@]11C(=CO)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCCCC5CC[C@H]4[C@@H]3C[C@@H]2O1 XEMAZQRIKQEVPH-NLXSHYKESA-N 0.000 title description 13
- 150000001875 compounds Chemical class 0.000 claims description 83
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
- 230000002438 mitochondrial effect Effects 0.000 claims description 58
- 239000003814 drug Substances 0.000 claims description 49
- -1 N(R') 2 Chemical group 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 45
- 208000024827 Alzheimer disease Diseases 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 40
- 208000035475 disorder Diseases 0.000 claims description 32
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
- 239000003826 tablet Substances 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 13
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 210000002569 neuron Anatomy 0.000 claims description 13
- 238000002560 therapeutic procedure Methods 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 210000003169 central nervous system Anatomy 0.000 claims description 10
- 230000007171 neuropathology Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 210000003205 muscle Anatomy 0.000 claims description 9
- 206010021143 Hypoxia Diseases 0.000 claims description 8
- 230000007954 hypoxia Effects 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000021642 Muscular disease Diseases 0.000 claims description 6
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 201000009623 Myopathy Diseases 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 239000004593 Epoxy Substances 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 230000000181 anti-adherent effect Effects 0.000 claims description 2
- 239000003911 antiadherent Substances 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 206010010121 compartment syndrome Diseases 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 2
- 230000005779 cell damage Effects 0.000 claims 2
- 208000037887 cell injury Diseases 0.000 claims 2
- KUBDPQJOLOUJRM-UHFFFAOYSA-N 2-(chloromethyl)oxirane;4-[2-(4-hydroxyphenyl)propan-2-yl]phenol Chemical group ClCC1CO1.C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 KUBDPQJOLOUJRM-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010049119 Emotional distress Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 101150016011 RR11 gene Proteins 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 229940068682 chewable tablet Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 230000009429 distress Effects 0.000 claims 1
- 239000007911 effervescent powder Substances 0.000 claims 1
- 239000007938 effervescent tablet Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 description 101
- 210000003470 mitochondria Anatomy 0.000 description 81
- 210000004027 cell Anatomy 0.000 description 67
- 239000000203 mixture Substances 0.000 description 64
- 229930105110 Cyclosporin A Natural products 0.000 description 43
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 43
- 108010036949 Cyclosporine Proteins 0.000 description 43
- 229960001265 ciclosporin Drugs 0.000 description 43
- 230000002407 ATP formation Effects 0.000 description 39
- 230000001225 therapeutic effect Effects 0.000 description 38
- UGTJLJZQQFGTJD-UHFFFAOYSA-N Carbonylcyanide-3-chlorophenylhydrazone Chemical compound ClC1=CC=CC(NN=C(C#N)C#N)=C1 UGTJLJZQQFGTJD-UHFFFAOYSA-N 0.000 description 36
- 210000004556 brain Anatomy 0.000 description 33
- 206010029260 Neuroblastoma Diseases 0.000 description 31
- 230000007423 decrease Effects 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 25
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 24
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 23
- 229940079593 drug Drugs 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- 229930195712 glutamate Natural products 0.000 description 22
- 229940049920 malate Drugs 0.000 description 22
- 230000000241 respiratory effect Effects 0.000 description 22
- 229940124597 therapeutic agent Drugs 0.000 description 20
- 241000700159 Rattus Species 0.000 description 18
- 238000011534 incubation Methods 0.000 description 18
- 239000011148 porous material Substances 0.000 description 18
- 230000001681 protective effect Effects 0.000 description 18
- 230000035806 respiratory chain Effects 0.000 description 17
- BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 16
- 230000004065 mitochondrial dysfunction Effects 0.000 description 15
- 230000004898 mitochondrial function Effects 0.000 description 14
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 14
- RZPAXNJLEKLXNO-UHFFFAOYSA-N (20R,22R)-3beta,22-Dihydroxylcholest-5-en Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C(O)CCC(C)C)C1(C)CC2 RZPAXNJLEKLXNO-UHFFFAOYSA-N 0.000 description 13
- BMZRVOVNUMQTIN-UHFFFAOYSA-N Carbonyl Cyanide para-Trifluoromethoxyphenylhydrazone Chemical compound FC(F)(F)OC1=CC=C(NN=C(C#N)C#N)C=C1 BMZRVOVNUMQTIN-UHFFFAOYSA-N 0.000 description 13
- 206010029350 Neurotoxicity Diseases 0.000 description 13
- 206010044221 Toxic encephalopathy Diseases 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 210000001700 mitochondrial membrane Anatomy 0.000 description 13
- 230000006540 mitochondrial respiration Effects 0.000 description 13
- 231100000228 neurotoxicity Toxicity 0.000 description 13
- 230000007135 neurotoxicity Effects 0.000 description 13
- 230000010627 oxidative phosphorylation Effects 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 230000003833 cell viability Effects 0.000 description 11
- 238000002648 combination therapy Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000000324 neuroprotective effect Effects 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000001988 toxicity Effects 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 9
- MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 9
- MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 9
- MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 9
- MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 9
- 241000208838 Asteraceae Species 0.000 description 9
- 239000000544 cholinesterase inhibitor Substances 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 230000006735 deficit Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 208000015122 neurodegenerative disease Diseases 0.000 description 9
- 229930191479 oligomycin Natural products 0.000 description 9
- MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 238000000540 analysis of variance Methods 0.000 description 8
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 8
- 239000012091 fetal bovine serum Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 230000037050 permeability transition Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 238000001061 Dunnett's test Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 7
- 229940080817 rotenone Drugs 0.000 description 7
- 230000002000 scavenging effect Effects 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 229960004793 sucrose Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000283074 Equus asinus Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001431818 Gynura japonica Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229930187386 myxothiazol Natural products 0.000 description 6
- XKTFQMCPGMTBMD-FYHMSGCOSA-N myxothiazol Chemical compound NC(=O)\C=C(\OC)[C@H](C)[C@@H](OC)\C=C\C1=CSC(C=2N=C(SC=2)[C@@H](C)\C=C\C=C\C(C)C)=N1 XKTFQMCPGMTBMD-FYHMSGCOSA-N 0.000 description 6
- XKTFQMCPGMTBMD-UHFFFAOYSA-N myxothiazol A Natural products NC(=O)C=C(OC)C(C)C(OC)C=CC1=CSC(C=2N=C(SC=2)C(C)C=CC=CC(C)C)=N1 XKTFQMCPGMTBMD-UHFFFAOYSA-N 0.000 description 6
- 230000004770 neurodegeneration Effects 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000004482 ATP Translocases Mitochondrial ADP Human genes 0.000 description 5
- 108010017236 ATP Translocases Mitochondrial ADP Proteins 0.000 description 5
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 5
- 206010036802 Progressive external ophthalmoplegia Diseases 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000012876 carrier material Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000003068 molecular probe Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004061 uncoupling agent Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 102100028247 Abl interactor 1 Human genes 0.000 description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 4
- 240000007472 Leucaena leucocephala Species 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 241000208292 Solanaceae Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000003287 bathing Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229960005069 calcium Drugs 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229960003530 donepezil Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 230000016273 neuron death Effects 0.000 description 4
- 230000002887 neurotoxic effect Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 108050004693 Abl interactor 1 Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010015995 Eyelid ptosis Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241001558017 Gynura Species 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 3
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 239000007891 compressed tablet Substances 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 3
- 229960004640 memantine Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 201000003004 ptosis Diseases 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 229960001685 tacrine Drugs 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000819038 Chichester Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 2
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108020005196 Mitochondrial DNA Proteins 0.000 description 2
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000012122 aqueous mounting media Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 229940096516 dextrates Drugs 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229940089027 kcl-40 Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 150000001455 metallic ions Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 201000002697 mitochondrial DNA depletion syndrome Diseases 0.000 description 2
- 230000007631 mitochondrial deficit Effects 0.000 description 2
- 230000006686 mitochondrial oxygen consumption Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- HTYPUNPKBFMFFO-UHFFFAOYSA-N platinum silver Chemical compound [Ag][Pt][Pt] HTYPUNPKBFMFFO-UHFFFAOYSA-N 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 210000001176 projection neuron Anatomy 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- QVVOJAYJPVCCOU-BKBMWLROSA-N (1R,2S,4S,6R,8S,9S,12S,13S)-5',9,13-trimethyl-7-methylidenespiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-16-ol Chemical compound O1CC(C)CC[C@@]11C(=C)[C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CCC(O)CC5CC[C@H]4[C@@H]3C[C@@H]2O1 QVVOJAYJPVCCOU-BKBMWLROSA-N 0.000 description 1
- RZPAXNJLEKLXNO-GFKLAVDKSA-N (22R)-22-hydroxycholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)[C@H](O)CCC(C)C)[C@@]1(C)CC2 RZPAXNJLEKLXNO-GFKLAVDKSA-N 0.000 description 1
- UBHXMSIBGRGDSX-VFGCUDCLSA-N (2s,3s,4s,5r,6r)-6-[2-[(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CO[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O UBHXMSIBGRGDSX-VFGCUDCLSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- ZCWPHDXKEDBCER-UHFFFAOYSA-N 2,5-diphenyl-2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=CC=CC=C1C1=[NH+]N(C=2C=CC=CC=2)N=N1 ZCWPHDXKEDBCER-UHFFFAOYSA-N 0.000 description 1
- QGKBSGBYSPTPKJ-UZMKXNTCSA-N 2,6-di-o-methyl-β-cyclodextrin Chemical compound COC[C@H]([C@H]([C@@H]([C@H]1OC)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O3)[C@H](O)[C@H]2OC)COC)O[C@@H]1O[C@H]1[C@H](O)[C@@H](OC)[C@@H]3O[C@@H]1COC QGKBSGBYSPTPKJ-UZMKXNTCSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- CTBYOENFSJTSBT-UHFFFAOYSA-N 2-oxobutanedioic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.OC(=O)CC(=O)C(O)=O CTBYOENFSJTSBT-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100028220 ABI gene family member 3 Human genes 0.000 description 1
- 101150088827 ABI4 gene Proteins 0.000 description 1
- 108050003506 ABL interactor 2 Proteins 0.000 description 1
- 102100028221 Abl interactor 2 Human genes 0.000 description 1
- 102100033639 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 1
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 101100215647 Aspergillus flavus (strain ATCC 200026 / FGSC A1120 / IAM 13836 / NRRL 3357 / JCM 12722 / SRRC 167) aflR gene Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KCGKYAORRXGWMN-UHFFFAOYSA-N CNS(=O)=O Chemical class CNS(=O)=O KCGKYAORRXGWMN-UHFFFAOYSA-N 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000010354 Coenzyme Q10 deficiency Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- BQTXJHAJMDGOFI-NJLPOHDGSA-N Dexamethasone 21-(4-Pyridinecarboxylate) Chemical compound O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)COC(=O)C1=CC=NC=C1 BQTXJHAJMDGOFI-NJLPOHDGSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000724234 Homo sapiens ABI gene family member 3 Proteins 0.000 description 1
- 101000724225 Homo sapiens Abl interactor 1 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 241000288904 Lemur Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000012419 Presenilin-2 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 101001124028 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Non-structural maintenance of chromosome element 6 Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000001646 Solanum asperum Nutrition 0.000 description 1
- 241001263253 Solanum asperum Species 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 230000009042 allosteric modification Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 description 1
- ZHZFKLKREFECML-UHFFFAOYSA-L calcium;sulfate;hydrate Chemical compound O.[Ca+2].[O-]S([O-])(=O)=O ZHZFKLKREFECML-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- RPBJOYICBFNIMN-RDWMNNCQSA-M dexamethasone sodium m-sulfobenzoate Chemical compound [Na+].O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)COC(=O)C1=CC=CC(S([O-])(=O)=O)=C1 RPBJOYICBFNIMN-RDWMNNCQSA-M 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003118 drug derivative Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 230000001614 effect on membrane Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000010200 folin Substances 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013289 male long evans rat Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000302 myotoxic Toxicity 0.000 description 1
- 230000003630 myotoxic effect Effects 0.000 description 1
- 230000001016 myotrophic effect Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- JSGHQDAEHDRLOI-UHFFFAOYSA-N oxomalononitrile Chemical compound N#CC(=O)C#N JSGHQDAEHDRLOI-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 229940126731 protein tyrosine phosphatase inhibitor Drugs 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- LHDNLMFZLXUSKX-UHFFFAOYSA-M sodium;hydrogen carbonate;pentanedioic acid Chemical compound [Na+].OC([O-])=O.OC(=O)CCCC(O)=O LHDNLMFZLXUSKX-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002182 synaptic membrane Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960001177 trimetazidine Drugs 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Description
WO 2006/107902 PCT/US2006/012380 USE OF SPIROSTENOLS TO TREAT MITOCHONDRIAL DISORDERS Related Application 5 This application claims priority from U.S. Provisional Application Serial No. 60/667,229 filed April 1, 2005 and to U.S. Provisional Application Serial No. 60/697,518 filed July 8, 2005, which applications are herein incorporated by reference. Background of the Invention 10 Mitochondria are specialized compartments present in every cell of the body except red blood cells, and are responsible for generating, by oxidative phosphorylation, more than 90% of the energy needed by the body to sustain life and support growth. When the mitochondrial respiratory chain fails, the energy level of the cell will rapidly decrease leading to the cell death and organ function 15 impairment. Depending on the organ considered, the impairment of the mitochondrial physiological function is involved in neurodegenerative diseases and disorders. These include those of the central nervous system, such as Alzheimer's Disease and Parkinson's Disease, and those affecting the peripheral nerves, such as muscular disorders (myopathies) and various kidney, liver and 20 respiratory disorders. Depending on how severe the mitochondrial disorder is, the illness can range in severity from mild to lethal. Whether the mitochondrial failure is a cause or a consequence of the condition experienced, protecting respiratory function is critical to restore the impaired physiological functions. In addition, 25 the preservation of the mitochondrial respiratory function is essential for the conservation of tissue required for a successful graft. There are no cures for mitochondrial diseases which have a genetic basis, but treatment can help reduce symptoms or delay or prevent the progression of the disease (M. Zeviani et al., Brain; 127: 2153 (2004)). Treatment is 30 individualized for each patient, depending on the nature and the severity of the disorder, although these palliative treatments will not reverse the damage already sustained. However, a number of experimental strategies are currently being assessed, including gene therapy and pharmacological intervention. One strategy consists of the introduction of modified genes or gene 35 products into mitochondria via the protein import machinery (G. Manfredi et al., 1 WO 2006/107902 PCT/US2006/012380 Natur. Genet., 30:394 (2002)) and inhibition of replication of mutant mtDNA by sequence-specific antigenomic peptide-nucleic acids (R.W. Taylor et al., Natur. Genet., 15:212 (1997)). These approaches are not yet employed clinically. In selected, isolated myopathy cases, reduction of heteroplasmic mutant 5 load was obtained by controlled muscle fiber damage and regeneration by mutation-free satellite cells, using myotoxic drugs (W. Irwin et al., J Biol. Chei., 277:2221 (2002)). However, this treatment was not effective in improving ptosis in five patients with progressive external ophthalmoplegia (PEO). 10 Creatine is the substrate for the synthesis of phosphocreatine and is the most abundant energy storage compound in muscle, heart and brain. An open trial of 81 patients with various neuromuscular disorders (including 17 with mitochondrial diseases) showed significant improvement of ischaemic isometric handgrip strength and non-ischemic isometric dorsiflexion torque. Another 15 placebo-controlled, double-blind, randomized crossover trial in 16 patients with chronic PEO or mitochondrial myopathy, however, did not find significant effects on exercise performance, eye movements, or activities of daily life (P.F. Chinnery et al., Am. J Med. Genet., 106:94 (2001)). Taken together, these data suggest that creatine may be effective in some, but not all mitochondrial 20 diseases. While Coenzyme Q10 is not effective in mtDNA-associated mitochondrial disease (N. Bresolin et al., J Neurol. Sci., 100:70 (1990)) it leads to marked improvement in 'primary' CoQ10 deficiency. Idebenone, a shorter chain analogue of Coenzyme Q10, appears to be effective in improving the 25 hypertrophic cardiomyopathy in Friedreich's ataxia (P. Rustin et al., Lancet, 354: 477 (1999); C. Mariotti et al., Neurology, 60:1676 (2003)). Thus, there is a continuing need for methods to treat mitrochondrial disorders, including mitochondrial diseases. 30 Summary of the Invention The present invention provides a therapeutic method comprising administering to a mammal, such as a human, afflicted with or threatened by, a mitochondrial disorder that is not a neuropathology of the central nervous system 2 WO 2006/107902 PCT/US2006/012380 comprising administering to said mammal an effective amount of a compound of formula (): R16 X R17 R12 R13 R 1 R1 R a R2 )_ R1_05 R9 R14 R3 R7 R4 R6 1 wherein each of R1, R2, R4, R7, R11, R12, and Ris, independently, is hydrogen, 5 (CI-Cs)alkyl, that is optionally inserted with -NR'-, -0-, -S-, -SO-, -SO 2 -, -0 S02-, -S02-0-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-NR'-, or -NR'-C(O)-; hydroxy, N(R') 2 , carboxyl, oxo, or sulfonic acid; R 3 is hydroxy, (CI-Cs)alkoxy, (C1-C 22 )alkylCO 2 or R'0 2
C(CH
2
)
2
-
8
CO
2 -, wherein (C 1
-C
22 )alkyl or (CH 2
)
2 -3 can optionally comprise 1-2 CH=CH units, 1-2 OH, and/or 1-2 epoxy substituents, 10 toluene-4-sulfonyloxy or benzoyloxy; each of R 6 , R 8 , R 9 , Rio, R 1 3 , R 1 4 , R 16 and
R
1 7, independently, is hydrogen, (C 1
-C
8 )alkyl, hydroxyl(CI-C 8 )alkyl, (C 1 Cs)alkoxy, or hydroxy; and X is 0, S, S(O), N(R'), N(Ac) or N(toluene-4 sulfonyloxy), wherein each R' is individually H, (C 1 -Cs)alkyl, phenyl or benzyl; or a 15 pharmaceutically acceptable salt thereof.
R
16 and/or R 17 are preferably CH 3 . Alkyl is preferably (C 2 -Cs)alkyl. Therefore, the present invention includes therapeutic methods of treating a mitochondrial disorder in a subject afflicted with or threatened by said 20 disorder, wherein said disorder is not a neuropathology of the central nervous system, comprising administering to the subject an effective amount of a compound of formula (II): H3C X CH3 R12 R13 R11 O R21 UR0 R8 R9 R14 R3 R7 R4 R6 (H) 3 WO 2006/107902 PCT/US2006/012380 wherein each of R 1 , R 2 , R 4 , R 7 , RI 1 , R 1 2 , and R 15 , independently, is hydrogen, (C 1 -Cs)alkyl, hydroxy, amino, carboxyl, oxo, sulfonic acid, or (C 1 C 8 )alkyl that is optionally inserted with -NH-, -N((CI-Cs)alkyl)-, -0-, -S-, -SO-, -S02-, -0-S02-, -S02-0-, -C(O)-, -C(0)-O-, -0-C(O)-, -C(O)-NR'-, or -NR' 5 C(O)-, wherein R' is H or (CI-Cs)alkyl; R 3 is hydroxy, (CI-C 6 )alkylCO 2 -,
HO
2
C(CH
2
)
2
CO
2 -, toluene-4-sulfonyloxy or benzoyloxy; each of R 6 , R 8 , R 9 , RIO,
R
1 3 , and R 1 4 , independently, is hydrogen, (CI-C 8 )alkyl, hydroxyl(CI-Cs)alkyl,
(CI-C
8 )alkoxy or hydroxy; and X is 0, N(H), N(Ac) or N(toluene-4 sulfonyloxy); or a pharmaceutically acceptable salt thereof. 10 As discussed in detail below, spirostenols, particularly 5,6 unsaturated spirostenols such as (22S,25S)-(20S)-spirost-5-en-3p-yl hexanoate, a 22R hydroxycholesterol derivative naturally occurring in Gynurajaponica (asteraceae), can provide a novel therapeutic strategy that works by its direct targeting of the mitochondrial respiratory chain, as well as its targeting of AP 15 which is toxic to mitochondria. (22S,25S)-(20S)-Spirost-5-en-3p-yl hexanoate also abolished the induced uncoupling of oxidative phosphorylation and amplified the effect of cyclosporin A, a potent blocker of mitochondrial membrane permeability transition pore, which suggest an effect on membrane permeability transition pore. 20 Mitochondrial disorders, including mitochondrial diseases that are not considered to be CNS neuropathologies, and that can be treated with the present method include the following: eye: retinitis pigmentosa, optical nerve atrophy; muscles: disorders of the extraoccular muscles (ptosis, acquired strabismus, ophthalmoplegia), crushed muscle syndrome (compartment syndrome); 25 mitochondrial dysfunction as a result of drug side-effect (i.e., highly active anti retroviral therapy, HAART); myopathy; heart: heart stroke, heart attack, heart conditions, heart disease, cardiomyopathy, and any cardiac mitochondrial dysfunction as a result of drug side-effect (i.e., HAART, mega-HAART, anti cancer drugs like anthracyclins); liver: hepatocellular dysfunctions; kidney and 30 the endocrine system: tubulopathy, diabetes; and respiratory disorders. The present invention also provides novel compounds of formulas I or II and compositions, such as pharmaceutical compositions comprising an effective amount of a compound of formula I and/or II in combination with a pharmaceutically acceptable carrier. 4 WO 2006/107902 PCT/US2006/012380 Brief Description of the Figures Fig. 1 Effect of increasing concentrations of SP-233 (10 to 100 pM) on the mitochondrial respiratory chain, assessed by monitoring the evolution of the 5 respiratory coefficient in rat brain mitochondria. This mitochondrial respiratory coefficient (MRC) is V3/V4. V4 is the basal 02 consumption, V3 is the 02 consumption after adding ADP (ATP production). The mitochondrial concentration was adjusted to 0.4 mg protein/ml. It is noteworthy that concentrations of SP-233 as low as 10 pM induced a 50% decrease in the MRC, 10 compared to control (p<0.001). Results are expressed as mean ± SD; comparisons between groups were made by an ANOVA followed by a Dunnett's test. Fig. 2 (a): Effect of SP-233 on CCCP-induced uncoupling of oxidative phosphorylation in rat brain mitochondria. To assess the effect of SP-233 on 15 CCCP-induced uncoupling of oxidative phosphorylation, the mitochondrial fraction was incubated for 3 min at 37'C in presence of SP-233 before adding malate/glutamate, followed 1 min later by the addition of CCCP. Exposure to the uncoupling agent CCCP (1 [M) increased the 02 consumption to 150% of the basal value (p<0.01), a change that reflected an increase in oxygen 20 consumption. At all concentrations tested (even at 1 pM), SP-233 abolished the metabolic effect of CCCP (p<0.001). This inhibitory effect of SP-233 on "uncoupling" was associated with decreases in the 02 consumption to 60-65% of the basal level and was concentration-independent. (b): Effect of SP-233 on CsA-induced hypoxia. Hypoxia was induced by adding CsA (1 sM) to the 25 medium bathing the mitochondria. This test was controlled by adding ADP in presence of CsA and absence of SP-233. SP-233, or its vehicle, was added first, and incubation was continued for 1.5 min before CsA was gently added. Then, the substrate malate/glutamate was added 1.5 min later and ADP 2.5 min later. Exposure to SP-233 did not inhibit the decrease in the MRC induced by CsA, 30 but on the contrary, the effect of CsA was amplified in a concentration dependent manner. Results are expressed as mean SD; comparisons between groups were made by an ANOVA followed by a Dunnett's test. Fig. 3 Effects of fresh and aged Ai -42 on the mitochondrial respiratory coefficient of rat brain mitochondria. Mitochondria were incubated in the 5 WO 2006/107902 PCT/US2006/012380 presence of ApI-42 for 1.5 min at 37'C before adding the substrates malate/glutamate. ADP was added 1 min after malate/glutamate. This experiment was controlled by omitting ADP. A31-42 significantly decreased the MRC even at the low concentration of 0.1 pM. The effect of the fresh amyloid 5 peptide on the MCR was more pronounced than that of the aged form, the respective decreases in MRC being 55-63% and 43-53%. Results are expressed as mean + SD; comparisons between groups were made by an ANOVA followed by a Dunnett's test. Fig. 4 Effects of SP-233 on modifications of the mitochondrial 10 respiratory coefficient induced by fresh or aged Ai-42 in rat brain mitochondria. Mitochondria were incubated in the presence of SP-233 for 3 min and in the presence of freshly prepared (a) or aged (b) AP1-42 for 1.5 min at 37 0 C before addition of malate/glutamate. ADP was added 1 min after the substrates malate/glutamate. The control for the effect of SP-233 versus A1 -42 was the 15 same as for the experiment without ADP. (a): Fresh A1-42 reduced the MRC by 71% compared to the control, and this effect was partially inhibited by SP-233. The most potent effect was observed with the lowest concentration of SP-233 which restored the MRC to 39% of the control value (38.56 ± 0.34 versus 28.93 1 1.75, p<0.001). (b): Aged A1l-42 reduced the MRC by 51% compared to the 20 control value, but SP-233 did not prevent this effect. Results are expressed as mean ± SD; comparisons between groups were made by an ANOVA followed by a Dunnett's test. Fig. 5 Assessment of the protective effect of SP-233 against A#1-42 induced toxicity in human neuroblastoma cells. The cellular toxicity of AO was 25 assessed after 72 h incubation of SK-N-AS neuroblastoma cells with A1l-42 (0.1, 1 and 10 pM) or vehicle and in the presence or absence of SP-233 (1 pLM) using the MTT assay. SP-233 (1 piM) prevented the neurotoxicity induced by the three concentrations ofAo1-42. Results are expressed as mean I SD; comparisons between groups were made by an ANOVA followed by Dunnett's test. 30 Neuroblastoma cells treated with A1-42 displayed strong immunoreactivity (which co-localized with complex II of the mitochondrial respiratory chain, indicating that Al1-42 was present inside the mitochondria). Treatment with SP-233 abolished Ao1-42 immunoreactivity, indicating its ability to block the entry of Ai-42 into the mitochondria. 6 WO 2006/107902 PCT/US2006/012380 Fig. 6 Effect of SP-233 on mitochondrial respiration. The Chemical formula of the spirostenol derivative (22R,25R)-20a-spirost-5-en-3B-yl hexanoate (SP-233) is shown in (a). The effect of increasing concentrations of SP-233 (1 aM to 100 pM) on the mitochondrial respiratory chain, assessed by 5 monitoring the evolution of the respiratory coefficient in isolated rat brain mitochondria, is shown in (b). This mitochondrial respiratory coefficient (MRC) is defined as V 3
/V
4 where V 4 is the basal 02 consumption and V 3 is the 02 consumption after adding ADP (ATP production). The mitochondrial concentration was adjusted to 0.4 mg protein/ml. Note that concentrations of 10 SP-233 as low as 1 fM resulted in a 40% decrease in the MRC, compared to the control (p<0.001). Results are expressed as means SD from three independent experiments performed in triplicate. Fig. 7 Effect of SP-233 on CCCP-induced uncoupling of oxidative phosphorylation and on CsA-induced hypoxia. (a) To assess the effect of SP-233 15 on CCCP-induced uncoupling of oxidative phosphorylation, the mitochondrial fraction was incubated for 3 min at 37'C in presence of SP-233 before adding malate/glutamate. CCCP was added 1 min later. Exposure to the uncoupling agent 1 pM CCCP increased the 02 consumption to 150% of the basal value (p<0.01). At all concentrations tested, SP-233 abolished the metabolic effect of 20 CCCP (p<0.001). SP-233's inhibitory effect on "uncoupling" was associated with a decrease in 02 consumption to 60-65% of the basal level and was concentration-independent. (b) Hypoxia was induced by adding 1 pLM CsA to the medium bathing the mitochondria. As a control, ADP was added in presence of CsA and in the absence of SP-233. SP-233, or its vehicle, was added first, and 25 incubation was continued for 1.5 min before CsA was gently added. The substrate malate/glutamate was added 1.5 min later, and ADP was added 2.5 min later. Exposure to SP-233 did not inhibit the decrease in the MRC induced by CsA. On the contrary, CsA's effect was amplified in a concentration-dependent manner. Results are expressed as means ± SD from three independent 30 experiments performed in triplicate. Fig. 8 Effects of fresh and aged AB1-42 on the mitochondrial respiratory coefficient of rat brain mitochondria. Mitochondria were incubated in the presence of ABI-4 2 for 1.5 min at 37 0 C before adding the substrates malate/glutamate. ADP was added 1 min after malate/glutamate. In these 7 WO 2006/107902 PCT/US2006/012380 experiments ADP was omitted from the incubation mixture. AB 1
-
42 significantly decreased the MIRC, even at a concentration of 0.1 pM. The effect of the fresh amyloid peptide on the MCR was more pronounced than that of the aged form, the respective decreases in IRC being 55-63% and 43-53%. Results are 5 expressed as means : SD from three independent experiments performed in triplicates. Fig. 9 Effects of SP-233 on changes in the MRC induced by fresh or aged AB 1
-
42 . Mitochondria were incubated in the presence of SP-233 for 3 min and in the presence of freshly prepared (a) or aged (b) AB 1-42 for 1.5 min at 10 37'C before addition of malate/glutamate. ADP was added 1 min after the addition of malate/glutamate. Controls reactions were performed in the absence of ADP. Fresh AB 1
-
42 reduced the MRC by 71% compared to the control, and this effect was partially inhibited by SP-233. The most potent effect was observed with the lowest concentration of SP 15 233 examined, which restored the MRC to 39% of the control value (38.56 h 0.34 vs. 28.93 ± 1.75, p<0.001). Aged AB 1
..
42 reduced the MRC by 51% compared to the control value, but SP-233 did not prevent this effect. Results are expressed as means ± SD from three independent experiments performed in triplicate. 20 Fig. 10 Assessment of the protective effect of SP-233 against AB 1
-
42 induced toxicity in human neuroblastoma cells. The cellular toxicity of AB was assessed 72 h after incubation of SK-N-AS cultures with AB 1-42 (0.1, 1 and 10 pM) or vehicle and in presence or absence of SP-233 (1 gM) using the MTT assay. Results are expressed as means : SD from three independent experiments 25 performed in triplicate. Fig. 11 Confocal microscopy analysis of the effect of SP-233 on mitochondrial uptake of AB1-42 in SK-N-AS human neuroblastoma cells. Representative images taken from healthy, uninjured (control) cells are shown in (al-4). These cultures did not receive any AB 1
-
42 or SP-233. Representative 30 images taken from SK-N-AS cells treated with AB 1
-
42 10 ptM for 3 hours are shown in (b 1-4). Representative images taken from SK-N-AS cells treated with
ABI-
42 10 pLM and SP-233 1 pM for 3 hours are shown in (cl-4). Cells were stained with DAPI nuclear counterstain (al, bl, and c1) and labeled for AB 1
-
42 (FITC; a2, b2, and c2) and complex II 70-kDa subunit (Texas red; a3, b3, and 8 WO 2006/107902 PCT/US2006/012380 c3). Merged images are shown in a4, b4, and c4. Neuroblastoma cells treated with ABl- 42 displayed strong immunoreactivity (b2) that co-localized with complex II of the mitochondrial respiratory chain (b4), and treatment with SP 233 abolished AJ3 1
-
42 immunoreactivity (c2). 5 Fig. 12 Neuroprotective effects of SP-233 against mitochondrial complex inhibitors in SK-N-AS cells. Five different mitochondrial toxins were added to SK-N-AS cultures 1 hour after the addition of SP-233 or its solvent. Rotenone, malonate, and myxothiazol were incubated for 24 hours in absence or presence of SP-233 before the cell viability measures were carried out. The duration of 10 incubation for KCN and oligomycin was 6 hours. Results are expressed as means ± SD from three independent experiments performed in triplicate. * p<0.05, ** p<0.01, *** p<0.001 compared to cultures not treated with SP-233. Fig. 13 Neuroprotective effects of SP-233 on SK-N-AS neuronal cells against PAO. PAO was added to cultures 1 hour after the addition of SP-233 or 15 its solvent. Cultures were incubated in PAO for 24 hours in the absence or presence of SP-233, prior to cell viability measurements. Results are expressed as means ± SD from three independent experiments performed in triplicate. ** p<0.01 compared to cells not treated with SP-233. Fig. 14 Effect of SP-233 on FCCP-induced uncoupling of the 20 mitochondrial respiratory chain in SK-N-AS cells. FCCP was added to SK-N AS cultures 1 hour after the addition of SP-233 or its solvent. Cultures were incubated in FCCP for 24 hours in the absence or presence of SP-233, before the cell viability measurements were performed. Results are expressed as means SD from three independent experiments performed in triplicate. ** p<0.01 25 compared to cells not treated with SP-233. Fig. 15 Schematic representation of the mitochondrial sites targeted by SP-233. The elements of the respiratory chain targeted by SP-233 are indicated with a green arrow. Dotted arrows denote a poor neuroprotective effect, and full green arrows denote a strong protective effect. The most pronounced effect was 30 observed against KCN, an inhibitor of complex IV, oligomycin, an inhibitor of the complex V, and PAO, a promoter of the MPT. 9 WO 2006/107902 PCT/US2006/012380 Detailed Description of the Invention As discussed hereinbelow, impairment of the mitochondrial respiratory chain has been extensively described in relation to Alzheimer's disease (AD), and it has been reported that A31-42 uncouples the mitochondrial respiratory 5 chain and promotes the opening of the membrane permeability transition (MPT) pores of mitochondria, leading to cell death. The spirostenol (22S,25S)-(20S) spirost-5-en-3#-yl hexanoate (SP-233) has been reported to protect neuronal cells against A3 1
..
42 toxicity by binding and inactivating the peptide. The present invention is based on the discovery that the protective effect of SP-233 also 10 results in protection of mitochondrial function. It was found that picomolar concentrations of A3l-42 decreased the mitochondrial respiratory coefficient in mitochondria isolated flom rat forebrain by a protective effect that was partially reversed by SP-233. This protective effect of SP-233 probably results from its direct targeting of the respiratory chain, as well as its targeting of A0 1
-
42 . 15 SP-233 also abolished the uncoupling of oxidative phosphorylation induced by carbonyl cyanide 3-chlorophenylhydrazone (CCCP) and amplified the effect of cyclosporin A (a potent blocker of mitochondrial MPT pores), suggesting an effect on MPT. These properties of SP-233 might contribute to its neuroprotective effect, since the uncoupling of the respiratory chain and the 20 opening of mitochondrial MPT pores are two deleterious events that could be triggered by A0 1
-
42 . Using human SK-N-AS neuroblastoma cells, it was further observed, using confocal microscopy, that Ao3- 42 accumulated in the mitochondrial matrix and that SP-233 completely scavenged AOI- 42 from the matrix. These results 25 indicate that Aol- 42 and SP-233 exert direct effects on the mitochondrial function of human neuronal cells, and that SP-233 (when present in the incubation mixture together with the amyloid peptide) can protect these cells against AO induced toxicity. Collectively, these findings indicate that A3l-42 may exert a direct toxic effect on mitochondrial function, and that SP-233 exerts its 30 neuroprotective effects by targeting A3 directly, thereby protecting the respiratory chain, and providing a family of compounds useful to treat mitochondrial diseases and disorders other than AD and other CNS neuropathologies. 10 WO 2006/107902 PCT/US2006/012380 As used herein, the term mitochondrial disorder encompasses art recognized mitochondrial diseases as well as conditions in which mitochondrial disorders or dysfunction plays a role in the onset symptomology, progression and/or outcome. The latter conditions include neurodegenerative diseases such 5 as Alzheimer's disease, Parkinson's disease, multiple sclerosis, or myotrophic lateral sclerosis as well as neuronal death induced by stroke, cerebral ischemia and other brain and spinal cord injuries. The use of spirostenols including (22S,25S)-(20S)-spirost-5-en-3-yl hexanoate to protect against A-induced neurotoxicity and their potential use in AD therapy has been reported (L. Lecanu 10 et al., Steroids, 69:1 (2004)) and is the subject of published PCT application WO/03/077869. The use of (22S,25S)-(20S)-spirost-5-en-3-yl hexanoate to protect mitochondria against a variety of stressors and its use in the therapy of various mitochondrial diseases has not been previously known. Mitochondrial diseases or mitochondrial myopathies are a group of 15 diseases affecting the mitochondria, that also interfere with the function of muscles. The group includes Kearns-Sayre syndrome, Leigh's syndrome, mitochondrial DNA depletion syndrome (MDS), mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS), myoclonus epilepsy with ragged red fibers (MERFF), mitochondrial 20 neurogastrointestinal encephalomyopathy (MNGIE), neuropathy, ataxia and retinitis pigmentosa (NARP), and progressive external ophthalmoplegia (PEO). The symptoms of mitochondrial myopathies include muscle weakness or exercise intolerance, heart failure (cardiomyopathy) or rhythm disturbances, dementia, movement disorders, stroke-like episodes, deafness, blindness, droopy 25 eyelids, limited mobility of the eyes, vomiting, and seizures. The prognosis for these disorders ranges in severity from progressive weakness to death. Thus, mitochondrial disorders can include disorders of the eye, such as optic nerve atrophy, ptosis, acquired stabimus, and ophthalomplegia. Mitochondrial dysfunction can be caused by crushed muscle syndrome (or compartment 30 syndrome), the side effects of drug therapies such as HAART and anti-cancer therapies involving drugs that damage the heart (e.g., anthracycline), hepatocellular dysfunction, endocrine tubulopathy and respiratory disorders. Most mitochondrial myopathies occur before the age of 20, and often begin with exercise intolerance or muscle weakness. During physical activity, 11 WO 2006/107902 PCT/US2006/012380 muscles may become easily fatigued or weak. Muscle cramping is rare, but may occur. Nausea, headache, and breathlessness are also associated with these disorders. The term "treat" or "treatment" as used herein refers to any treatment of a 5 disorder or disease associated with a disease or disorder related to mitochondria, in a subject, and includes, but is not limited to, preventing the disorder or disease from occurring in a subject who may be predisposed to the disorder or disease, but has not yet been diagnosed as having the disorder or disease; inhibiting the disorder or disease, for example, arresting the development of the disorder or 10 disease; relieving the disorder or disease, for example, causing regression of the disorder or disease; or relieving the condition caused by the disease or disorder, for example, stopping the symptoms of the disease or disorder. As used herein, "mitochondrial disorder" or "mitochondrial disease" is intended to encompass all disorders disclosed herein. 15 The present method can also be used to prevent or reduce mitochondrial disorders in vitro, as in organs or tissues awaiting or undergoing transplantation. The term "prevent" or "prevention," in relation to a disease or disorder related to mitochondria, in a subject, means no disease or disorder development if none had occurred, or no further disorder or disease development if there had 20 already been development of the disorder or disease, or no symptoms to logically observable signs of the disease. Preferred stereoisomers are 3S, as well as 1OR and 13S, and are also 20S, 22S and 25S wherein the carbon skeleton is numbered in accord with spirosten 3-ol numbering. Thus, a preferred compound of formula (I or II) is (22S,25S) 25 (20S)-spirost-5-en-3p-yl hexanoate (SP233). Note that the carbon atoms shown in formula (I) or (II) are saturated with hydrogen unless otherwise indicated. Unless defined otherwise, each of the term "alkyl," the prefix "alk" (as in alkoxy), and the suffix "-alkyl" (as in hydroxyalkyl) refers to a C 1
-
8 hydrocarbon chain, linear (e.g., butyl) or branched (e.g., isobutyl). Alkylene, alkenylene, and 30 alkynylene refer to divalent C 1
.
8 alkyl (e.g., ethylene), alkene, and alkyne radicals, respectively. Preferably, alkyl is (C1-C 6 )alkyl, such as butyl, hexyl, methyl, ethyl, propyl or isopropyl. The term "alkyl" includes cycloakyl, (cycloalkyl)alkyl and alkyl(cycloalkyl)alkyl. The term "alkenyl" likewise 12 WO 2006/107902 PCT/US2006/012380 includes alkyl comprising 1-2 CH=CH units, as well as the corresponding cycloalkenyl moieties. Specifically, (CI-Cs)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, heptyl or octyl; (C 3 -Cs)cycloalkyl can be 5 monocyclic, bicyclic or tricyclic and includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.2] octanyl or norbornyl, as well as various terpene and terpenoid structures. (C 3
-C
6 )cycloalkyl(CI-C 2 )alkyl includes the foregoing cycloalkyl and can be cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 2-cyclobutylethyl, 2 10 cyclopentylethyl, or 2-cyclohexylethyl. Heterocycloalkyl includes cycloalkyl wherein the cycloalkyl ring system is monocyclic, bicyclic or tricyclic and optionally comprises 1-2 S, non-peroxide 0 or N(R') as well as 4-8 ring carbon atoms; such as morpholinyl, piperidinyl, piperazinyl, indanyl, 1,3-dithian-2-yl, and the like. Any cycloalkyl or heterocycloalkyl ring system optionally includes 15 1-3 double bonds or epoxy moieties and optionally is substituted with 1-3 OH,
(CI-C
6 )alkanoyloxy, (CO), (CI-C 6 )alkyl or (C 2
-C
6 )alkynyl. (CI-Cs)Alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 3-pentoxy, or hexyloxy; (C 2
-C
6 )alkenyl can be vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,-pentenyl, 2-pentenyl, 3-pentenyl, 20 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl; hydroxy(CI-Cs)alkyl or hydroxy (C 1 -Cs)alkoxyl can be alkyl substituted with 1 or 2 OH groups, such as alkyl substituted with 1 or 2 OH groups such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2 hydroxypropyl, 3-hydroxypropyl, 1-hydroxybutyl, 4-hydroxybutyl, 3,4 25 dihydroxybutyl, 1-hydroxypentyl, 5-hydroxypentyl, 1-hydroxyhexyl, or 6 hydroxyhexyl; (CI-C 22 )alkylCO 2 - can be acetoxy, propanoyloxy, butanoyloxy, isobutanoyloxy, pentanoyloxy or hexanoyloxy, or (C 8
-C
22
)CO
2 - can represent the residue of a naturally occurring fatty acid. In one embodiment of the invention, R 10 and/or R 12 are CH 3 . 30 In another embodiment of the invention, R 16 and R 17 are CH 3 . In a further embodiment of the invention, R 1 , R 2 and/or R 12 can be H or OH. In another embodiment, R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , R 9 , R 11 , R 1 2 , R 14 and R 15 are H. 13 WO 2006/107902 PCT/US2006/012380
R
2 can be (C 1
-C
22 )alkylCO 2 -, including (C 8
-C
22 )alkylCO 2 - or (C 1 C 6 )alkylCO 2 -, or can be OH or O(Ci-C 8 )alkyl, or HO 2
C(CH
2
)
2
CO
2 -. X can be 0 or NR' including NH or NAc.
R
3 may also be OR 23 wherein R 23 is a removable hydroxy-protecting 5 group such as tosyl, mesyl, tri(C 1
-C
4 )alkylsilyl, THP, Eto(Et), benzyl, benzoyloxycarbony and the like. C 3
-(C
8
-C
22 ) fatty acid esters of compounds in which C 3 is hydroxysubstituted are also within the invention, wherein the fatty acid is preferably naturally occurring. Shown below in Table 1 are several compounds of formula (I) and (II) 10 described above that can be used to practice this invention: Table 1. Denomination Chemical Name Origin SP224 (20a)-25 -methyl-(22R,26)-azacyclofurost-5-en-3 - Solanuni asperum ol (solanaceae) SP226 (204)-254-methyl-N-acetyl-(22R,26)-azacyclofurost- Solanum asperum 5-en-34-ol (solanaceae) SP227 (22R,254)-(20a)-spirost-5-en-(2ax,3 )-diol Gynurajaponica (asteraceae) SP229 (20a)-254-methyl-N-paratoluenesulfonyl-(22R,26)- Solanun aviculare azacyclofurost-5-en-34-yl paratoluenesulfonate (solanaceae) SP230 (22R,254)-(20a)-(14c,20ac)-spirost-5-en-(3p,12p)- Gynurajaponica diol (asteraceae) SP231 (22R,25S)-(204)-spirost-5-en-3 -ol Gynurajaponica (asteraceae) SP232 (22R,254)-(20a)-spirost-5-en-3p-yl benzoate Gynura sp. (asteraceae) SP233 (22S,25S)-(20S)-spirost-5-en-3p-yl hexanoate Gynura sp. (asteraceae) SP234 (22R,254)-(20c)-spirost-5-en-(1,3 )-diol Gynurajaponica (asteraceae) SP235 (22R,25S)-(20a)-spirost-5-en-3 -ol Gynurajaponica (asteraceae) SP236 (22R,25S)-(20c)-spirost-5-en-3 -yl succinate Gynura sp. (asteraceae) SP238 (20a)-25S-methyl-N-acetyl-(22S,26)-azacyclofurost- Solanuin asperum 5-en-3p-yl propanoate (solanaceae) An effective amount of an efficacious compound of the invention can be formulated with a pharmaceutically acceptable carrier to form a pharmaceutical 15 composition before being administered for treatment of a disease related to 14 WO 2006/107902 PCT/US2006/012380 impaired mitochondrial function. "An effective amount" or "pharmacologically effective amount" refers to the amount of the compound which is required to confer therapeutic effect on the treated subject. The interrelationship of dosages for animals and humans (based on milligrams per square meter of body surface) 5 is described by Freireich et al., Cancer Chemother. Rep., 50, 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, 1970, 537. Effective doses can be based on in vitro concentrations of the present compounds found to be effective to inhibit the toxicity of AP or to otherwise 10 protect mitochondria. Doses of the present compounds useful to treat a model neuronal cell line are disclosed below. Effective doses will also vary, as recognized by those skilled in the art, depending on the route of administration, the excipient usage, and the optional co-administration with other therapeutic agents. 15 Toxicity and therapeutic efficacy of the active ingredients can be determined by standard pharmaceutical procedures, e.g., for detennining LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio 20 LD 50
/ED
5 0 . Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects. 25 Included in the methods, kits, combinations and pharmaceutical compositions of the present invention are the crystalline forms (e.g., polymorphs), enantiomeric forms, isomeric forms and tautomers of the described compounds and the phannaceutically-acceptable salts thereof. Illustrative pharmaceutically acceptable salts are prepared from formic, acetic, propionic, 30 succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 15 WO 2006/107902 PCT/US2006/012380 2-hydroxyethanesulfonic, sulfanilic, cyclohexylaminosulfonic, algenic, b hydroxybutyric, galactaric and galacturonic acids. The term "prodrug" refers to a drug or compound (active moiety) that elicits the pharmacological action results from conversion by metabolic 5 processes within the body. Prodrugs are generally considered drug precursors that, following administration to a subject and subsequent absorption, are converted to an active or a more active species via some process, such as a metabolic process. Other products from the conversion process are easily disposed of by the body. Prodrugs generally have a chemical group present on 10 the prodrug which renders it less active and/or confers solubility or some other property to the drug, such as an ester or acyl group. Once the chemical group has been cleaved from the prodrug the more active drug is generated. Prodrugs may be designed as reversible drug derivatives and utilized as modifiers to enhance drug transport to site-specific tissues. The design of prodrugs to date 15 has been to increase the effective water solubility of the therapeutic compound for targeting to regions where water is the principal solvent. For example, Fedorak, et al., Am. J. Physiol., 269, G210-218 (1995), describe dexamethasone beta-D-glucuronide. McLoed, et al., Gastroenterol.,106, 405-413 (1994), describe dexamethasone-succinate-dextrans. Hochhaus, et al., Biomed. Chrom., 20 6, 283-286 (1992), describe dexamethasone-21-sulphobenzoate sodium and dexamethasone-21-isonicotinate. Additionally, J. Larsen and H. Bundgaard, Int. J. Pharmaceutics, 37, 87 (1987) describe the evaluation of N-acylsulfonamides as potential prodrug derivatives. J. Larsen et al., Int. J. Pharmaceutics, 47, 103 (1988) describe the evaluation of N-methylsulfonamides as potential prodrug 25 derivatives. Prodrugs are also described in, for example, Sinkula et al., J. Pharm. Sci., 64, 181-210 (1975). Prodrugs are also useful as synthetic intermediates in the preparation of other compounds of formulas (I) or (II), by synthetic interconversions known to the art. For example, see, I.T. Harrison, Compendium of Organic Synthetic Methods, Wiley-Interscience (1971), for 30 methods useful to interconvert spirostenol substituents. The term "derivative" refers to a compound that is produced from another compound of similar structure by the replacement or substitution of one atom, molecule or group by another. For example, a hydrogen atom of a compound 16 WO 2006/107902 PCT/US2006/012380 may be substituted by alkyl, acyl, amino, etc., to produce a derivative of that compound. "Plasma concentration" refers to the concentration of a substance in blood plasma or blood serum. 5 "Drug absorption" or "absorption" refers to the process of movement from the site of administration of a drug toward the systemic circulation, for example, into the bloodstream of a subject. "Bioavailability" refers to the extent to which an active moiety (drug or metabolite) is absorbed into the general circulation and becomes available at the 10 site of drug action in the body. "Metabolism" refers to the process of chemical transfonnations of drugs in the body. "Pharmacodynamics" refers to the factors which determine the biologic response observed relative to the concentration of drug at a site of action. "Pharmacokinetics" refers to the factors which determine the attainment 15 and maintenance of the appropriate concentration of drug at a site of action. "Plasma half-life" refers to the time required for the plasma drug concentration to decrease by 50% from its maximum concentration. The use of the term "about" in the present disclosure means "approximately," and encompasses variations in parameters that would arise 20 during practice of the relevant art. Illustratively, the use of the term "about" indicates that dosages outside the cited ranges may also be effective and safe, and such dosages are also encompassed by the scope of the present claims. The term "measurable serum concentration" means the serum concentration (typically measured in mg, pg, or ng of therapeutic agent per ml, 25 dl, or 1 of blood serum) of a therapeutic agent absorbed into the bloodstream after administration. The term "pharmaceutically acceptable" is used adjectivally herein to mean that the modified noun is appropriate for use in a pharmaceutical product. Pharmaceutically acceptable salts include metallic ions and organic ions. More 30 preferred metallic ions include, but are not limited to appropriate alkali metal (Group Ia) salts, alkaline earth metal (Group Ia) salts and other physiological acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc in their usual valences. Preferred organic ions include protonated tertiary amines and quaternary ammonium 17 WO 2006/107902 PCT/US2006/012380 cations, including in part, trimethylamine, diethylamine, N,N' dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplary pharmaceutically acceptable acids include without limitation hydrochloric acid, 5 hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid, pyruvic acid oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like. 10 The compositions of the present invention are usually administered in the form of pharmaceutical compositions. These compositions can be administered by any appropriate route including, but not limited to, oral, nasogastric, rectal, transdermal, parenteral (for example, subcutaneous, intramuscular, intravenous, intramedullary and intradermal injections, or infusion techniques 15 administration), intranasal, transmucosal, implantation, vaginal, topical, buccal, and sublingual. Such preparations may routinely contain buffering agents, preservatives, penetration enhancers, compatible carriers and other therapeutic or non-therapeutic ingredients. The present invention also includes methods employing a phannaceutical 20 composition that contains one or more compound of formula I or II associated with pharmaceutically acceptable carriers or excipients. As used herein, the terms "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipients" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and 25 the like. The use of such media and agents for ingestible substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the compositions, its use is contemplated. Supplementary active ingredients can also be incorporated into the compositions. In making the compositions of the present invention, the compositions(s) can be mixed with a 30 pharmaceutically acceptable excipient, diluted by the excipient or enclosed within such a carrier, which can be in the form of a capsule, sachet, or other container. The carrier materials that can be employed in making the composition of the present invention are any of those commonly used excipients in 18 WO 2006/107902 PCT/US2006/012380 pharmaceutics and should be selected on the basis of compatibility with the active drug and the release profile properties of the desired dosage form. Illustratively, pharmaceutical excipients are chosen below as examples: (a) Binders such as acacia, alginic acid and salts thereof, cellulose 5 derivatives, methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, magnesium aluminum silicate, polyethylene glycol, gums, polysaccharide acids, bentonites, hydroxypropyl methylcellulose, gelatin, polyvinylpyrrolidone, polyvinylpyrrolidone/vinyl acetate copolymer, crospovidone, povidone, polymethacrylates, hydroxypropylmethylcellulose, hydroxypropylcellulose, 10 starch, pregelatinized starch, ethylcellulose, tragacanth, dextrin, cyclodextrins, microcrystalline cellulose, sucrose, or glucose, and the like. (b) Disintegration agents such as starches, pregelatinized corn starch, pregelatinized starch, celluloses, cross-linked carboxymethylcellulose, sodium starch glycolate, crospovidone, cross-linked polyvinylpyrrolidone, 15 croscarmellose sodium, microcrystalline cellulose, a calcium, a sodium alginate complex, clays, alginates, gums, or sodium starch glycolate, and any disintegration agents used in tablet preparations. (c) Filling agents such as lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose 20 powder, dextrose, dextrates, dextran, starches, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like. (d) Surfactants such as sodium lauryl sulfate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts, 25 glyceryl monostearate, PluronicTM line (BASF), and the like. (e) Solubilizer such as citric acid, succinic acid, fumaric acid, malic acid, tartaric acid, maleic acid, glutaric acid sodium bicarbonate and sodium carbonate and the like. (f) Stabilizers such as any antioxidation agents, buffers, or acids, and the 30 like, can also be utilized. (g) Lubricants such as magnesium stearate, calcium hydroxide, talc, sodium stearyl fumarate, hydrogenated vegetable oil, stearic acid, glyceryl behapate, magnesium, calcium and sodium stearates, stearic acid, talc, waxes, 19 WO 2006/107902 PCT/US2006/012380 boric acid, sodium benzoate, sodium acetate, sodium chloride, DL-leucine, polyethylene glycols, sodium oleate, or sodium lauryl sulfate, and the like. (h) Wetting agents such as oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene 5 sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium oleate, or sodium lauryl sulfate, and the like. (i) Diluents such lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose, dibasic calcium phosphate, sucrose-based diluents, confectioner's sugar, monobasic calcium sulfate monohydrate, calcium sulfate 10 dihydrate, calcium lactate trihydrate, dextrates, inositol, hydrolyzed cereal solids, amylose, powdered cellulose, calcium carbonate, glycine, or bentonite, and the like. (j) Anti-adherents or glidants such as talc, corn starch, DL-leucine, sodium lauryl sulfate, and magnesium, calcium, or sodium stearates, and the 15 like. (k) Pharmaceutically compatible carrier comprises acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl 20 lactylate, carrageenan, monoglyceride, diglyceride, or pregelatinized starch, and the like. Additionally, drug formulations are discussed in, for example, Remington's The Science and Practice of Pharmacy (2000). Another discussion of drug formulations can be found in Liberman, H.A. and Lachman, L., Eds., 25 Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980. The tablets or granules comprising the inventive compositions may be film coated or enteric-coated. Besides being useful for human treatment, the present invention is also useful for other subjects including veterinary animals, reptiles, birds, exotic 30 animals and farm animals, including mammals, rodents, and the like. Mammal includes a primate, for example, a monkey, or a lemur, a horse, a dog, a pig, or a cat. A rodent includes a rat, a mouse, a squirrel, or a guinea pig. The pharmaceutical compositions of the present invention are useful where administration of an inhibitor of mitochondrial toxicity is indicated. It is 20 WO 2006/107902 PCT/US2006/012380 believed that these compositions will be particularly effective in the treatment of mitochondrial diseases. For treatment of a neurodegenerative disorder/mitochondrial disorder, compositions of the invention can be used to provide a dose of a compound of 5 the present invention in an amount sufficient to elicit a therapeutic response, e.g., reduction of drug-induced mitochondrial toxicity, for example a dose of about 5 ng to about 1000 mg, or about 100 ng to about 600 mg, or about 1 mg to about 500 mg, or about 20 mg to about 400 mg. Typically a dosage effective amount will range from about 0.000 1 mg/kg to 1500 mg/kg, more preferably 1 to 1000 10 mg/kg, more preferably from about 1 to 150 mg/kg of body weight, and most preferably about 50 to 100 mg/kg of body weight. A dose can be administered in one to about four doses per day, or in as many doses per day to elicit a therapeutic effect. Illustratively, a dosage unit of a composition of the present invention can typically contain, for example, about 5 ng, 50 ng 100 ng, 500 ng, 1 15 mg, 10 mg, 20 mg, 40 mg, 80 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 700 mg, 800 mg, 900 mg, or 1000 mg of a compound of the present invention. The dosage form can be selected to accommodate the desired frequency of administration used to achieve the specified dosage. The amount of the unit dosage form of the 20 composition that is administered and the dosage regimen for treating the condition or disorder depends on a variety of factors, including, the age, weight, sex and medical condition, of the subject, the severity of the condition or disorder, the route and frequency of administration, and this can vary widely, as is well known. 25 In one embodiment of the present invention, the composition is administered to a subject in an effective amount, that is, the composition is administered in an amount that achieves a therapeutically effective dose of a compound of the present invention in the blood serum of a subject for a period of time to elicit a desired therapeutic effect. Illustratively, in a fasting adult human 30 (fasting for generally at least 10 hours) the composition is administered to achieve a therapeutically effective dose of a compound of the present invention in the blood serum of a subject from about 5 minutes after administration of the composition. In another embodiment of the present invention, a therapeutically effective dose of the compound of the present invention is achieved in the blood 21 WO 2006/107902 PCT/US2006/012380 serum of a subject at about 10 minutes from the time of administration of the composition to the subject. In another embodiment of the present invention, a therapeutically effective dose of the compound of the present invention is achieved in the blood serum of a subject at about 20 minutes from the time of 5 administration of the composition to the subject. In yet another embodiment of the present invention, a therapeutically effective dose of the compound of the present invention is achieved in the blood serum of a subject at about 30 minutes from the time of administration of the composition to the subject. In still another embodiment of the present invention, 10 a therapeutically effective dose of the compound of the present invention is achieved in the blood serum of a subject at about 40 minutes from the time of administration of the composition to the subject. In one embodiment of the present invention, a therapeutically effective dose of the compound of the present invention is achieved in the blood serum of a subject at about 20 minutes 15 to about 12 hours from the time of administration of the composition to the subject. In another embodiment of the present invention, a therapeutically effective dose of the compound of the present invention is achieved in the blood serum of a subject at about 20 minutes to about 6 hours from the time of administration of the composition to the subject. In yet another embodiment of 20 the present invention, a therapeutically effective dose of the compound of the present invention is achieved in the blood serum of a subject at about 20 minutes to about 2 hours from the time of administration of the composition to the subject. In still another embodiment of the present invention, a therapeutically 25 effective dose of the compound of the present invention is achieved in the blood serum of a subject at about 40 minutes to about 2 hours from the time of administration of the composition to the subject. And in yet another embodiment of the present invention, a therapeutically effective dose of the compound of the present invention is achieved in the blood serum of a subject at 30 about 40 minutes to about 1 hour from the time of administration of the composition to the subject. In one embodiment of the present invention, a composition of the present invention is administered at a dose suitable to provide a blood serum concentration with a half maximum dose of a compound of the present 22 WO 2006/107902 PCT/US2006/012380 invention. Illustratively, a blood serum concentration of about 0.01 to about 1000 nM, or about 0.1 to about 750 nM, or about 1 to about 500 nM, or about 20 to about 1000 nM, or about 100 to about 500 nM, or about 200 to about 400 nM is achieved in a subject after administration of a composition of the present 5 invention. Contemplated compositions of the present invention provide a therapeutic effect over an interval of about 5 minutes to about 24 hours after administration, enabling once-a-day or twice-a-day administration if desired. In one embodiment of the present invention, the composition is administered at a 10 dose suitable to provide an average blood serum concentration with a half maximum dose of a compound of the present invention of at least about 1 tg/ml, or at least about 5 Ig/ml, or at least about 10 pg/ml, or at least about 50 pg/ml, or at least about 100 ptg/ml, or at least about 500 Ig/ml, or at least about 1000 tg/ml in a subject about 10, 20, 30, or 40 minutes after administration of the 15 composition to the subject. The amount of therapeutic agent necessary to elicit a therapeutic effect can be experimentally detennined based on, for example, the absorption rate of the agent into the blood serum, the bioavailability of the agent, and the potency for treating the disorder. It is understood, however, that specific dose levels of 20 the therapeutic agents of the present invention for any particular subject depends upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, and diet of the subject (including, for example, whether the subject is in a fasting or fed state), the time of administration, the rate of excretion, the drug combination, and the severity of 25 the particular disorder being treated and form of administration. Treatment dosages generally may be titrated to optimize safety and efficacy. Typically, dosage-effect relationships from in vitro and/or in vivo tests initially can provide useful guidance on the proper doses for subject administration. Studies in animal models generally may be used for guidance regarding effective dosages 30 for treatment of gastrointestinal disorders or diseases in accordance with the present invention. In terms of treatment protocols, it should be appreciated that the dosage to be administered will depend on several factors, including the particular agent that is administered, the route administered, the condition of the particular subject, etc. Generally speaking, one will desire to administer an 23 WO 2006/107902 PCT/US2006/012380 amount of the compound that is effective to achieve a serum level commensurate with the concentrations found to be effective in vitro for a period of time effective to elicit a therapeutic effect. Thus, where a compound is found to demonstrate in vitro activity at, for example, a half-maximum effective dose of 5 200 nM, one will desire to administer an amount of the drug that is effective to provide about a half-maximum effective dose of 200 nM concentration in vivo for a period of time that elicits a desired therapeutic effect, for example, treating a disorder related to high beta-amyloid-induced neurotoxicity and other indicators as are selected as appropriate measures by those skilled in the art. 10 Determination of these parameters is well within the skill of the art. These considerations are well known in the art and are described in standard textbooks. In order to measure and determine the effective amount of a compound of the present invention to be delivered to a subject, serum compound of the present invention concentrations can be measured using standard assay 15 techniques. Contemplated compositions of the present invention provide a therapeutic effect over an interval of about 30 minutes to about 24 hours after administration to a subject. In one embodiment compositions provide such therapeutic effect in about 30 minutes. In another embodiment compositions 20 provide therapeutic effect over about 24 hours, enabling once-a-day administration to improve patient compliance. The present methods, kits, and compositions can also be used in combination ("combination therapy") with another pharmaceutical agent that is indicated for treating or preventing a mitochondrial disease, such as, for 25 example, creatinine. When used in conjunction with the present invention, that is, in combination therapy, an additive or synergistic effect may be achieved such that many if not all of unwanted side effects can be reduced or eliminated. The reduced side effect profile of these drugs is generally attributed to, for example, the reduced dosage necessary to achieve a therapeutic effect with the 30 administered combination. The phrase "combination therapy" embraces the administration of a composition of the present invention in conjunction with another pharmaceutical agent that is indicated for treating or preventing a mitochondrial disorder in a subject, as part of a specific treatment regimen intended to provide a beneficial 24 WO 2006/107902 PCT/US2006/012380 effect from the co-action of these therapeutic agents for the treatment of a neurodegenerative and/or a mitochondrial disorder. The beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic 5 agents. Administration of these therapeutic agents in combination typically is carried out over a defined time period (usually substantially simultaneously, minutes, hours, days, weeks, months or years depending upon the combination selected). "Combination therapy" generally is not intended to encompass the administration of two or more of these therapeutic agents as part of separate 10 monotherapy regimens that incidentally and arbitrarily result in the combinations of the present invention. "Combination therapy" is intended to embrace administration of these therapeutic agents in a sequential manner, that is, where each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic 15 agents, in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single tablet or capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules, or tablets for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent 20 can be effected by any appropriate route. The composition of the present invention can be administered orally or nasogastric, while the other therapeutic agent of the combination can be administered by any appropriate route for that particular agent, including, but not limited to, an oral route, a percutaneous route, an intravenous route, an intramuscular route, or by direct absorption through 25 mucous membrane tissues. For example, the composition of the present invention is administered orally or nasogastric and the therapeutic agent of the combination may be administered orally, or percutaneously. The sequence in which the therapeutic agents are administered is not narrowly critical. "Combination therapy" also can embrace the administration of the therapeutic 30 agents as described above in further combination with other biologically active ingredients, such as, but not limited to, an analgesic, for example, and with non drug therapies, such as, but not limited to, surgery. The therapeutic compounds which make up the combination therapy may be a combined dosage form or in separate dosage forms intended for 25 WO 2006/107902 PCT/US2006/012380 substantially simultaneous administration. The therapeutic compounds that make up the combination therapy may also be administered sequentially, with either therapeutic compound being administered by a regimen calling for two step administration. Thus, a regimen may call for sequential administration of 5 the therapeutic compounds with spaced-apart administration of the separate, active agents. The time period between the multiple administration steps may range from, for example, a few minutes to several hours to days, depending upon the properties of each therapeutic compound such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the therapeutic compound, 10 as well as depending upon the effect of food ingestion and the age and condition of the subject. Circadian variation of the target molecule concentration may also determine the optimal dose interval. The therapeutic compounds of the combined therapy whether administered simultaneously, substantially simultaneously, or sequentially, may 15 involve a regimen calling for administration of one therapeutic compound by oral route and another therapeutic compound by an oral route, a percutaneous route, an intravenous route, an intramuscular route, or by direct absorption through mucous membrane tissues, for example. Whether the therapeutic compounds of the combined therapy are administered orally, by inhalation spray, 20 rectally, topically, buccally, sublingually, or parenterally (for example, subcutaneous, intramuscular, intravenous and intradermal injections), separately or together, each such therapeutic compound will be contained in a suitable pharmaceutical formulation of pharmaceutically-acceptable excipients, diluents or other formulations components. 25 For oral administration, the pharmaceutical composition can contain a desired amount of a compound of fonnula (I) or (II) and be in the form of, for example, a tablet, a hard or soft capsule, a lozenge, a cachet, a troche, a dispensable powder, granules, a suspension, an elixir, a liquid, or any other form reasonably adapted for oral administration. Illustratively, such a pharmaceutical 30 composition can be made in the form of a discrete dosage unit containing a predetermined amount of the active compound such as a tablet or a capsule. Such oral dosage forms can further comprise, for example, buffering agents. Tablets, pills and the like additionally can be prepared with enteric coatings. 26 WO 2006/107902 PCT/US2006/012380 Pharmaceutical compositions suitable for buccal or sublingual administration include, for example, lozenges comprising the active compound in a flavored base, such as sucrose, and acacia or tragacanth, and pastilles comprising the active compound in an inert base such as gelatin and glycerin or 5 sucrose and acacia. Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise, for example, wetting agents, emulsifying and suspending agents, and 10 sweetening, flavoring, and perfuming agents. Examples of suitable liquid dosage forms include, but are not limited to, aqueous solutions comprising the active compound and beta-cyclodextrin or a water soluble derivative of beta-cyclodextrin such as sulfobutyl ether beta cyclodextrin; heptakis-2,6-di-O-methyl-beta-cyclodextrin; hydroxypropyl-beta 15 cyclodextrin; and dimethyl-beta-cyclodextrin. The pharmaceutical compositions of the present invention can also be administered by injection (intravenous, intramuscular, subcutaneous). Such injectable compositions can employ, for example, saline, dextrose, or water as a suitable carrier material. The pH value of the composition can be adjusted, if 20 necessary, with suitable acid, base, or buffer. Suitable bulking, dispersing, wetting or suspending agents, including mannitol and polyethylene glycol (such as PEG 400), can also be included in the composition. A suitable parenteral composition can also include an active compound lyophilized in injection vials. Aqueous solutions can be added to dissolve the composition prior to injection. 25 The phannaceutical compositions can be administered in the form of a suppository or the like. Such rectal formulations preferably contain the active compound in a total amount of, for example, about 0.075 to about 75% w/w, or about 0.2 to about 40% w/w, or about 0.4 to about 15% w/w. Carrier materials such as cocoa butter, theobroma oil, and other oil and polyethylene glycol 30 suppository bases can be used in such compositions. Other carrier materials such as coatings (for example, hydroxypropyl methylcellulose film coating) and disintegrants (for example, croscarmellose sodium and cross-linked povidone) can also be employed if desired. 27 WO 2006/107902 PCT/US2006/012380 The subject compounds may be free or entrapped in microcapsules, in colloidal drug delivery systems such as liposomes, microemulsions, and macroemulsions. These pharmaceutical compositions can be prepared by any suitable 5 method of pharmaceutics, which includes the step of bringing into association active compound of the present invention and a carrier material or carriers materials. In general, the compositions are uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the product. For example, a tablet can be prepared by 10 compressing or molding a powder or granules of the compound, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing, in a suitable machine, the compound in a free-flowing form, such as a powder or granules optionally mixed with a binding agent, lubricant, inert diluent and/or surface active/dispersing agent(s). Molded tablets can be made by 15 molding, in a suitable machine, the powdered compound moistened with an inert liquid diluent. Tablets of the present invention can also be coated with a conventional coating material such as OpadryTM White YS- 1-1 8027A (or another color) and the weight fraction of the coating can be about 3% of the total weight of the 20 coated tablet. The compositions of the present invention can be formulated so as to provide quick, sustained or delayed release of the compositions after administration to the patient by employing procedures known in the art. When the excipient serves as a diluent, it can be a solid, semi-solid or liquid material, which acts as a vehicle, carrier or medium for the active 25 ingredient. Thus, the compositions can be in the fonn of tablets, chewable tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), soft and hard gelatin capsules and sterile packaged powders. In one embodiment of the present invention, the manufacturing processes 30 may employ one or a combination of methods including: (1) dry mixing, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion. Lachman et al., The Theory and Practice of Industrial Pharmacy (1986). 28 WO 2006/107902 PCT/US2006/012380 In another embodiment of the present invention, solid compositions, such as tablets, are prepared by mixing a therapeutic agent of the present invention with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of the therapeutic agent and the excipient. 5 When referring to these preformulation compositions(s) as homogeneous, it is meant that the therapeutic agent is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms, such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described herein. 10 Compressed tablets are solid dosage forms prepared by compacting a formulation containing an active ingredient and excipients selected to aid the processing and improve the properties of the product. The term "compressed tablet" generally refers to a plain, uncoated tablet for oral ingestion, prepared by a single compression or by pre-compaction tapping followed by a final 15 compression. The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. 20 A variety of materials can be used for such enteric layers or coatings, including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate. Use of a long-term sustained release implant may be suitable for treatment of mitochondrial disorders in patients who need continuous 25 administration of the compositions of the present invention. "Long-term" release, as used herein, means that the implant is constructed and arranged to deliver therapeutic levels of the active ingredients for at least 30 days, and preferably 60 days. Long-term sustained release implants are well known to those of ordinary skill in the art and include some of the release systems 30 described above. In another embodiment of the present invention, the compound for treating a mitochondrial disorder comes in the form of a kit or package containing one or more of the therapeutic compounds of the present invention. These therapeutic compounds of the present invention can be packaged in the 29 WO 2006/107902 PCT/US2006/012380 form of a kit or package in which hourly, daily, weekly, or monthly (or other periodic) dosages are arranged for proper sequential or simultaneous administration. The present invention further provides a kit or package containing a plurality of separately-packaged dosage units, adapted for 5 successive daily administration, each dosage unit comprising at least one of the therapeutic compounds of the present invention. This drug delivery system can be used to facilitate administering any of the various embodiments of the therapeutic compounds of the present invention. In one embodiment, the system contains a plurality of dosages to be administered daily or weekly. The kit or 10 package can also contain the agents utilized in combination therapy to facilitate proper administration of the dosage forms. The kits or packages also contain a set of instructions for the subject. The invention will be further described by reference to the following detailed examples wherein the following abbreviations are used: 15 AChEI, acetylcholinesterase inhibitor; A0, f-amyloid peptide; ADDLs, amyloid-derived diffusible ligands; ANT, adenine nucleotide translocase; APP, amyloid precursor protein; CCCP, carbonyl cyanide 3-chlorophenylhydrazone; FCCP, carbonyl cyanide p-trifluoromethoxy-phenylhydrazone; CsA, cyclosporin A; MPT, membrane permeability transition; MRC, mitochondrial respiratory 20 coefficient; PAO, phenylarsine oxide; SP-233, (22S,25S)-(20S)-spirost-5-en-3fl yl hexanoate; SP-233, (22R,25R)-(20a)-spirost-5-en-3#-y hexanoate. Mitochondrial permeability transition (MPT) may be further defined as a nonspecific increase in the permeability of the inner mitochondrial membrane that occurs under adverse conditions, such as an increase in mitochondrial Ca" 2 25 content of the mitochondrial matrix or oxidative stress, and which causes the assembly (opening) of non-specific pores ("megachannels") in the mitochondrial inner membrane, leading to a loss of mitochondrial membrane potential, an uncoupling of mitochondrial respiration, and cellular energy failure, all of which can contribute to cell death. 30 30 WO 2006/107902 PCT/US2006/012380 Example 1. Use of SP-233 to Protect Mitochondrial Function A. Materials and methods 1. Materials APt1-2 peptide was purchased from American Peptide Company 5 (Sunnyvale, CA, USA) and stored at -80*C. The antibody anti-complex II was purchased from Molecular Probes (Eugene, OR, USA) and the antibody anti Ab..
42 was from Signet Laboratories (Dedham, MA, USA). The spirostenol, (22S,25S)-(20S)-spirost-5-en-33-yl hexanoate (SP-233) was purchased from Interbioscreen (Moscow, Russia). Cyclosporin A (CsA) and carbonyl cyanide 3 10 chlorophenyihydrazone (CCCP) were obtained from Sigma (St. Louis, MO, USA). Dulbecco's Minimum Essential Medium (DMEM), fetal bovine serum (FBS) and SK-N-AS human neuroblastoma cells were purchased form ATCC (Manassas, VA, USA). 15 2. Mitochondrial isolation procedure Male Long-Evans rats weighing 230-280 g were used. After decapitation, the brain was rapidly removed and homogenized on ice in a Potter-Elvejhem homogenizer (Eurostar, IKA-Verke, Staufen, Germany) containing 6 ml of isolation buffer (TRIS 20 mM, sucrose 250 mM, KCl 40 mM, EGTA 2 mM, 20 bovine serum albumin 1 mg/ml; pH 7.2 at 4'C). The homogenate was centrifuged at 2000xg for 8 min to remove cell debris and nuclei. The mitochondria-containing supernatant was centrifuged at 12000xg for 10 min. The pellet was resuspended in 300 ptl of respiratory buffer (D-mannitol 300 mM, KC1 10 mM, KH2PO4 10 mM, MgCl2 5 mM; pH 7.2 at 37C). This pellet is 25 highly enriched in mitochondria (Zini et al. 1996). The protein concentration of the mitochondrial suspension was determined by the method of Lowry et al. 1951. 3. Preparation of the different solutions 30 ApI-4 2 solution was reconstituted with fresh distilled water to provide a concentration of 500 [tM. ApI-4 2 was used as freshly reconstituted or in an aggregated form after having been "aged" by incubating the solution for 48 h at 4'C. Both solutions were diluted with the respiratory buffer (see above) before use and then added directly to the mitochondria at the desired concentration. In 31 WO 2006/107902 PCT/US2006/012380 experiments conducted with neuroblastoma cells (see below), only the freshly reconstituted A P2 solution was used. SP-233, CCCP and CsA were first dissolved in N,N-dimethylformamide (DMF) and then diluted in fresh distilled water. 5 4. Monitoring of mitochondrial respiration Mitochondrial functions were studied using an Oxytherm (Hansatech, Norfolk, UK) linked to a PC (Compaq, PIII 400 MHz). The 37'C thermostated incubation chamber of the Oxytherm was connected to a platinum-silver Clarck 10 electrode for 02 detection. 02 consumption was monitored as a marker of mitochondrial function and viability in the presence of ADP (precursor for ATP) in the presence or absence of CCCP (an uncoupling agent for oxidative phosphorylation), or CsA (an inhibitor of the MPT pore). Measurement of 02 consumption permitted calculation of the mitochondrial respiratory coefficient 15 (MRC) which is V 3
/V
4 . V 4 is the basal 02 consumption, V 3 is the 02 consumption after adding ADP (ATP production). The effect of increasing concentrations of SP-233 (1 pM to 1 nM) on the mitochondrial respiratory chain was assessed by monitoring the evolution of MRC. The concentration of mitochondria was adjusted to 0.4 mg protein/ml using respiratory buffer. 20 Mitochondria were activated by addition of malate/glutamate as substrates of complex I of the respiratory chain. State 2 is the baseline rate of mitochondrial oxygen consumption. When ATP synthesis was initiated by addition of ADP, the rate of oxygen consumption increased dramatically to reach state 3. When the supply of ADP had been depleted, the rate of 02 consumption returned to 25 baseline (state 2) which was called state 4 (Chance and Williams 1956). Controls for each experiment corresponded to basal respiration in the presence of ADP. 5. Effect of SP-233 on CCCP-induced uncoupling of oxidative phosphorylation 30 Addition of CCCP (1 tM) uncouples the respiratory chain reaction and increases 02 consumption. To assess the effect of SP-233 on CCCP-induced uncoupling, the mitochondrial fraction was incubated for 3 min at 37'C in presence of SP-233 before adding malate/glutamate, followed 1 min later by the addition of CCCP. 32 WO 2006/107902 PCT/US2006/012380 6. Assessment of the effect of SP-233 on CsA-induced hypoxia Hypoxia was induced by adding CsA (1 tM) to the incubation medium bathing the mitochondria (Zini et al. 1996). This test was controlled by adding 5 ADP in the presence of CsA and absence of SP-233. As described above, SP 233 or its vehicle was added first and incubation was carried out for 1.5 min before addition of CsA. Then, the substrate malate/glutamate was added 1.5 min later, and ADP was added 2.5 min later. 10 7. Assessment of the protective effect of SP-233 against API 4 2 -induced mitochondrial dysfunction SP-233 was present in the incubation mixture for 3 min and Api- 2 for 1.5 min at 37'C before addition of the substrates malate/glutamate. ADP was added 1 min after addition of malate/glutamate. Control for the effect of SP-233 15 versus Api-4 2 was the same as for the experiment conducted in the absence of ADP. 8. Assessment of the protective effect of SP-233 against A3 1
.
42 -induced toxicity in human neuroblastoma cells 20 Human neuroblastoma SK-N-AS cells were seeded in 96-well plates (7x 104 cells/well) in DMEM containing 10% FBS and cultured in 5% CO 2 and 95% humidity. AP1-4 2 (0.1, 1 and 10 gM) or its vehicle was then added and incubation was continued for 72 h in the presence or absence of SP-233 (1 IM). The cellular toxicity of AO was assessed using the 3-(4,5-dimethylthiazol-2-yl) 25 2,5-diphenyl tetrazolium bromide (MTT) assay (Trevigen, Gaithersburg, MD). 9. Immunocytochemical analysis of Ap 1 -4 2 uptake by mitochondria of human neuroblastoma cells 30 Human neuroblastoma SK-N-AS cells were seeded on 13-mm diameter coverslips (20,000 cells/coverslip) and incubated overnight at 37'C, 5% CO 2 , in DMEM containing 10% FBS. AP31-42 (10 piM) or its vehicle was then added and incubation was continued for 3 h in the presence or absence of SP-233 (1 pM). To assess mitochondrial uptake of Ap 1 -4 2 , a co-localization study was 33 WO 2006/107902 PCT/US2006/012380 performed using a mouse monoclonal antibody Anti-OxPhos Complex II 70-kDa subunit raised against complex II of the mitochondrial respiratory chain (Molecular Probes, Eugene, OR, USA) and a rabbit polyclonal antibody raised against amino acid residues 33-42 of Api- 2 (Signet Laboratories, Dedham, MA, 5 USA). Neuroblastoma cells were washed with phosphate-buffered saline (PBS) 1X, fixed with methanol at -20'C and rinsed with PBS IX. Cells were then blocked with PBS 1X containing 10 % donkey serum for 30 min and then incubated for 24 h at 4'C with the first primary antibody raised against complex 11 (1/200) in PBS 1X solution containing 1.5% donkey serum and 0.01% Triton 10 X100. After washing the preparation 3 times with PBS 1X, a donkey anti-mouse rhodamine-labeled secondary antibody (Jackson ImmunoResearch, West Grove, PA, USA) was added at a 1/200 dilution and incubation was continued for 2 h at room temperature. The primary antibody raised against amino acids 33-42 of Api- 2 was then used following the same protocol at a 1/500 dilution. Positive 15 staining was revealed using a donkey-anti-rabbit secondary antibody labeled with the fluorescent marker Alexa Fluor@ 488 (Molecular Probes, Eugene, OR, USA). Coverslips were then mounted with an aqueous mounting medium containing 4',6-diamidino-2-phenylindole-2-hydrochloride (DAPI) (Vector Laboratories. Burlingame, CA, USA). Confocal images were taken using an 20 Olympus Fluoview BX61 Laser Scanning microscope. 10. Statistical analysis For each experiment, the results are expressed as means ± SD. Comparisons between groups were made by an ANOVA followed by a 25 Dunnett's test. B. Results 1. Effect of SP-233 on mitochondrial respiratory control SP-233 was studied at concentrations of 10, 30 and 100 pM. At a 30 concentration as low as 10 pM, SP-233 induced a significant 50% decrease in the MRC of rat brain mitochondria, as compared to the control group (p<0.001) (Fig. 1). Although the differences in the effects induced by various concentrations of SP-233 are not significant, the results do tend to display a 34 WO 2006/107902 PCT/US2006/012380 concentration-effect relationship since the MRC was progressively decreased over the concentration range of 10-100 pM. 2. Effect of SP-233 on CCCP- or CsA-induced modification of the 5 mitochondrial respiratory coefficient The uncoupling agent CCCP at 1 gM increased the 02 consumption of rat brain mitochondria to 150% of the basal value (p<0.01) (Fig. 2a). All concentrations of SP-23 3 that were tested (1-1000 pM) completely inhibited this metabolic effect of CCCP (p<0.001). The inhibition of CCCP-induced 10 uncoupling by SP-233 was associated with decreases in 02 consumption values to 60-65% of the basal level, and was concentration-independent. SP-233 did not counteract the decrease in the MRC induced by CsA, but on the contrary, it amplified this effect of CsA in a concentration-dependent manner (Fig. 2b). 15 3. Effects of fresh and aged Ao 1
-
42 on the mitochondrial respiratory coefficient
A#
1
-
42 significantly decreased the MRC of rat brain mitochondria even when it was present at a concentration as low as 0.1 pM (Fig. 3). This effect was more pronounced with the fresh amyloid peptide than with the aged form, the 20 respective inhibitory effects being 55-63% and 43-53%. This difference may be revealing that the non-aggregated form of A# 1
-
42 penetrates into the mitochondria to a greater extent than the aged, aggregated form of the peptide. 4. Effects of SP-233 on modifications of the mitochondrial respiratory 25 coefficient induced by fresh and aged A# 1
-
42 Fresh A0 1
-
42 reduced the MRC by 71% compared to the control, and this effect was partially inhibited by SP-233 (Fig. 4a). At the lowest concentration of SP-233 that was tested (1 pM), the MRC was restored to about 40% of the control value, and the MRC was significantly increased in comparison with the 30 value obtained with A1- 42 alone (38.56 ± 0.34 versus 28.93 ± 1.75, p<0.001). Aged A0 1
-
42 reduced the MRC by 51% compared to the control but SP-233 did not significantly prevent this effect (Fig. 4b). 35 WO 2006/107902 PCT/US2006/012380 5. Effect of SP-233 on A# 1
..
4 2 -induced toxicity on SK-N-AS human neuroblastoma cells Fig. 5 shows the effect of SP-233 on the Al- 42 induced decrease in SK N-AS cell viability. SP-233 1 piM prevented the neurotoxicity induced by the 5 three concentrations of AO 1
..
42 used by 19%, 26% and 28%, respectively (p<0.01). 6. Effect of SP-233 on Al 1
-
42 entry into the mitochondria of SK-N-AS human neuroblastoma cells 10 Neuroblastoma cells treated with Afl 1 -42 displayed strong immunoreactivity that co-localized with complex II of the mitochondrial respiratory chain, providing evidence that Afl- 42 entered, and was present inside, the mitochondria. Treatment with SP-233 abolished Ao 1
-
42 immunoreactivity, indicating that it blocked the entry of Al 1
-
42 into the cell and the mitochondria. 15 C. Discussion It is well known that AD is clinically characterized by a progressive impairment of cognitive processes and memory loss. Since the early days, this "mnesic" aspect of the disease has been related to the degeneration of central 20 cholinergic pathways, reflected as a decrease in synaptic concentrations of acetylcholine (ACh). Thus, drug development research has been focused mainly on restoring the ACh levels in the brain, and has led to the development of the acetylcholinesterase inhibitors (AChEIs), tacrine being the prototype of this class of compounds. However, despite promising clinical data, the beneficial effects of 25 tacrine have been modest, and despite the development of a new generation of AChEIs, represented by rivastigmine, galantamine and donepezil, the delay of symptom onset in AD patients has not been shortened, as compared to tacrine. This short (I to 2 years) delay in the further progression of AD symptoms (Tariot and Winblad, 2001; Waldemar et al. 2001; Grossberg et al. 2004), 30 although precious for the patients and their relatives, is probably due to the progressive degeneration of cholinergic neurons and is a limitation to the use of the AChEIs. Moreover, a recent study performed on 565 community-resident patients with mild-to-moderate AD indicated that donepezil is not cost effective, with benefits below minimally relevant thresholds (Courtney et al. 2004). Since, 36 WO 2006/107902 PCT/US2006/012380 no major advance has been made in AD drug development, even though memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist has recently been approved for treating moderately to severe AD (Livingston and Katona 2004), there remains an urgent need to develop agents that are more efficient 5 than AChEIs. The etiology of AD is well documented only for the familial early-onset form of the disease, which involves a mutation of the APP, presenilin-1 or presenilin-2 gene. In contrast, the cause of the late-onset sporadic form of AD, which represents about 95% of all AD cases, remains to be established. Many 10 theories have emerged, and among these it has been proposed that an energetic failure due to mitochondrial impairment and oxidative damage may be at the origin of AD (Schulz et al. 1997; Beal, 2000). Evidence that mitochondrial dysfunction is involved in AD etiology, together with the recent finding that SP-233 (a naturally occurring spirostenol) 15 can protect neuronal PC12 cells against A0 1
-
42 -induced neurotoxicity (Lecanu et al. 2004), that led us to examine the capacity of SP-233 to restore the function of isolated mitochondria that were impaired by exposure to Afl 1
-
42 . Taken together, the present findings indicate that SP-233 has the potential to influence basic mechanisms which are associated with A3 and which have been implicated in 20 the pathogenesis of AD. The effect of Afl on mitochondrial function has been extensively investigated during the past ten years and the data generated by these studies has indicated various effects of the peptide that could lead to mitochondria dysfunction. Afl 1
-
42 and the fragment Afl 25
-
35 have been shown to inhibit 25 respiration and the activities of key enzymes, such as succinate dehydrogenase, a-ketoglutarate dehydrogenase, pyruvate dehydrogenase and cytochrome oxidase, in neuronal mitochondria (Kaneko et al. 1995; Casley et al. 2002a). Inhibition of the different complexes of the respiratory chain has also been reported to occur in neuronal mitochondria exposed to Afl 2 5
-
35 (Pereira et al. 30 1998; Canevari et al. 1999;Casley et al. 2002b) and this same peptide fragment promoted pore-opening that is associated with the MPT (Moreira et al. 2001; Moreira et al. 2002; Bachurin et al. 2003). Results presented herein above show further that A13- 42 inhibits mitochondrial respiration of rat brain mitochondria, as revealed by a decrease in 37 WO 2006/107902 PCT/US2006/012380 the MRC, and that this inhibition occurs at A0 1
-
42 concentrations as low as 0.1 pM with both freshly prepared and aged forms of the peptide (see Fig. 3). The inhibitory effect is more pronounced with the fresh form probably because polymeric forms of Al-42 would traverse mitochondrial membranes to a lesser 5 extend than the monomeric form or oligomeric forms such as ADDLs, these latter forms therefore being more likely to exert their detrimental effects on the respiratory chain and being defacto more toxic. Also, the lack of protection by SP-233 of mitochondria submitted to the aged/aggregated form of Al- 42 (see Fig. 4) might be due to an inability of SP-233 to bind the aggregated form of the 10 amyloid peptide in the same way that it binds the monomeric form. SP-233 was able to partially prevent the decrease in MRC induced by freshly prepared Al 1
-
42 and protect mitochondrial function, confirming previous data which showed a restoring effect of SP-233 on the ATP synthesis of PC12 cells exposed to A0 1
-
42 (Lecanu et al. 2004). As SP-233 was active in very low 15 concentrations (picomolar range), its mechanism of action might be relatively specific. The present data also confirms recent results which showed that SP-233 protected neuronal cells against Ao 1
..
42 neurotoxicity by binding the monomeric form of the peptide and inhibiting the fonnation of the neurotoxic oligomeric ADDLs (Lecanu et al. 2004). 20 The confocal microscopy analysis performed on human neuroblastoma cells, in showing that Aol-42 co-localized with complex II of the respiratory chain, indicates that Aol- 42 can cross both cell and the mitochondrial membranes. When SP-233 and Aol- 42 were both present in the incubation medium immunocytochemical staining corresponding to the amyloid peptide was 25 completely suppressed, and this "scavenging" effect of SP-233 was accompanied by a partial restoration of the MRC. In addition, SP-233 prevented, although partially, the neurotoxic effect of Aol- 42 on the same human neuroblastoma cells. This finding is of particular interest in view of recent results which have indicated that amyloid-deposits are present in the mitochondria of cortical 30 pyramidal neurons of post-mortem AD brain (Femandez-Vizarra et al. 2004). These histological features have been described as being a very early event in the progression of the disease, appearing before the formation of paired-helical filaments and leading to neuronal death. 38 WO 2006/107902 PCT/US2006/012380 After the binding and "scavenging" effects of SP-233 on A# 1
-
42 had been established, the possibility that a direct effect of SP-233 on the mitochondria might result in an additive protective effect against A#1-42 was investigated. In this regard, it had been previously demonstrated that A0 promotes the opening of 5 MPT pores in brain mitochondria, leading to functional impairment, and that this effect is abolished by CsA (Moreira et al. 2001; Bachurin et al. 2003; Abramov et al. 2004). The present experiments show that SP-233, like CsA, decreases the MRC. SP-233 also amplifies the effect of the CsA, suggesting that it has CsA like properties and thereby inhibits MPT pore-opening, which could contribute 10 to its protective effect against A 1 -42 -induced mitochondrial dysfunction. SP-233 was also able to abolish the uncoupling of oxidative phosphorylation induced by CCCP (see Fig. 2a). It has been shown that A#1- 42 disrupts mitochondrial membrane structure (Kremer et al. 2001; Rodrigues et al. 2001) and that mitochondrial membrane fluidity may be altered in AD brain 15 (Mecocci et al, 1996), both phenomena leading to mitochondrial uncoupling. Therefore, even though the "recoupling" effect of SP-233 cannot yet be fully clarified, it might contribute to the restoration of mitochondrial function described herein. Moreover, a combination of the scavenging effect of SP-233 (presumably involving its modulation of MPT pores) and its re-coupling effect 20 might explain why SP-233 counteracted the effect of Al- 42 at concentrations as low as 1 pM. Example 2. The Spirostenol (22R,25R)-20a-spirost-5-en-3B-yl Hexanoate Blocks Mitochondrial Uptake of AB in Neuronal Cells and Prevents AB 25 Induced Impairment of Mitochondrial Function A. Materials and methods 1. Materials ABi 1
-
42 peptide was purchased from American Peptide Company (Sunnyvale, CA). The anti-complex II antibody was purchased from Molecular 30 Probes (Eugene, OR), and the antibody anti-AB13-42 was from Signet Laboratories (Dedham, MA). Spirostenol (SP-233) was purchased from Interbioscreen (Moscow, Russia). Cyclosporin A (CsA), carbonyl cyanide 3 chlorophenylhydrazone (CCCP), carbonyl cyanide p-trifluoromethoxy phenylhydrazone (FCCP), rotenone, malonate, myxothiazol, potassium cyanide 39 WO 2006/107902 PCT/US2006/012380 (KCN), oligomycin, and phenylarsine oxide (PAO) were obtained from Sigma (St Louis, MO). Dulbecco's Minimum Essential Medium (DMEM), fetal bovine serum (FBS), and SK-N-AS human neuroblastoma cells were purchased form ATCC (Manassas, VA). 5 2. Isolation of mitochondrial fractions To isolate mitochondrial fractions, rats weighing 230-350 g were decapitated, and the brain was rapidly removed and homogenized on ice in a Potter-Elvejhem homogenizer (Eurostar, IKA-Verke, Staufen, Germany) 10 containing 6 ml of ice-cold isolation buffer (TRIS 20 mM, sucrose 250 mM, KCl 40 mM, EGTA 2 mM, bovine serum albumin 1 mg/ml; pH 7.2). The homogenate was centrifuged at 2000xg for 8 min at 4'C to remove cell debris and nuclei. The mitochondria-containing supernatant was centrifuged at 12000xg for 10 min at 4'C. The pellet was resuspended in 300 p1l of respiratory 15 buffer (D-mannitol 300 mM, KCl 10 mM, KH 2 PO4 10 mM, MgCl 2 5 mM; pH 7.2 at 37C). This pellet is highly enriched in mitochondria (Zini et al. 1996). The protein concentration of the mitochondrial suspension was determined by the method of Lowry. 20 3. Measurement of mitochondrial respiration Mitochondrial respiration was measured using an Oxytherm (Hansatech, Norfolk, UK) linked to a PC (Compaq, PIII 400 MHz). The 37'C incubation chamber of the Oxytherm was connected to a platinum-silver Clarck electrode for 02 detection. 02 consumption was employed as a marker of mitochondrial 25 respiration in the presence of ADP (precursor for ATP) and in the presence or absence of the following: CCCP (an uncoupling agent for oxidative phosphorylation), CsA (an inhibitor of the membrane permeability transition pore), or ABI3 4 2 . Measurement of 02 consumption allowed for calculation of the mitochondrial respiratory coefficient (MRC)- defined as V 3
/V
4 where 30 V 4 is the basal 02 consumption and V 3 is the 02 consumption after adding ADP (ATP production). The final mitochondrial concentration was adjusted to 0.4 mg protein/mL using respiratory buffer. Mitochondria were activated by the addition of malate/glutamate, substrates of complex I of the respiratory chain. State 2 is defined as the baseline rate of mitochondrial oxygen consumption. 40 WO 2006/107902 PCT/US2006/012380 When ATP synthesis was initiated by addition of ADP, the rate of oxygen consumption increased dramatically to reach state 3. When the supply of ADP had been depleted, the rate of 02 consumption returned to baseline (state 2), which was called state 4 (Chance and Williams 1956). The affects of all 5 experimental treatments on respiration were compared to baseline respiration, or mitochondrial respiration in the presence of only ADP. To test the effects of SP-233 on mitochondrial dysfunction induced by CCCP, isolated mitochondria were incubated in SP-233 for 3 min at 37*C before adding malate/glutamate. One minute later, CCCP was added. To test the effects 10 of SP-233 on mitochondrial dysfunction induced by CsA, isolated mitochondria were incubated in SP-233 for 1.5 min before the addition of CsA. Malate/glutamate was added 1.5 min later, and ADP was added 2.5 min later. Finally, to test the affect of SP-233 on ABi4 2 -induced mitochondrial dysfunction, mitochondrial fractions were incubated in SP-233 for 3 min and 15 ABil- 2 for 1.5 min at 37 0 C before addition of malate/glutamate. ADP was added 1 min after addition of malate/glutamate. In all experiments, SP-233, CCCP, and CsA were first dissolved in N,N-dimethylformamide (DMF) and then diluted in fresh distilled water. AI 1
-
2 employed in these experiments was reconstituted with fresh distilled water to a concentration of 500pM. ABI- 2 was 20 used as freshly reconstituted or in an aggregated form after having been "aged" by incubating the solution for 48 h at 4'C. Both solutions were diluted with the respiratory buffer before use and then added directly to the mitochondria to achieve the desired concentration. 25 4. Cell Culture Human neuroblastoma SK-N-AS cells were seeded in 96-well plates (7x10 4 cells/well) in DMEM containing 10% FBS and were cultured in 5% CO 2 and 95% humidity. Cultures were treated with the following in the presence or absence of varying concentrations of SP-233: A 1 4 2 (0.1, 1, and 10 pM), 30 rotenone (50 nM), malonate (100 mM), myxothiazol (0.3 gM), KCN (12 mM), oligomycin (0.5 pg/ml), FCCP (3 pM), and PAO (0.25 pM). Cell viability was measured using the 3-( 4 ,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay according to manufacturer's instructions (Trevigen, Gaithersburg, MD). For experiments involving ABI 1 4 2 , cell viability was 41 WO 2006/107902 PCT/US2006/012380 measured 72 hours after the insult in the presence or absence of 1pM AB1 4 2 . Only the freshly reconstituted ABi-4 2 solutions were used. For experiments involving mitochondrial toxins (rotenone, malonate, myxothiazol, KCN, and oligomycin), cell viability was measured 6 or 24 hours after the insult in the 5 presence or absence of 1, 3, 10, 30, or 100gM ABi3 1 2 . SP-233 was added to cultures 1 hour prior to the addition of the mitochondrial toxins. For experiments involving FCCP and PAO, parallel cell cultures were incubated with or without increasing concentrations of SP-233, ranging from 1 to 100 gM, one hour prior to the addition of FCCP or PAO. Cell viability was 10 assessed 24 hours later. FCCP, rotenone, malonate, myxothiazol, KCN, oligomycin, and PAO were all first dissolved as a stock solution in ethanol before being diluted in culture medium to reach the indicated final concentrations. The percentage of ethanol in the culture medium was 0.09%. 15 5. Immunocytochemical analysis of AB1l42 Human neuroblastoma SK-N-AS cells were seeded on 13-mm diameter coverslips (20,000 cells/coverslip) and incubated overnight at 37'C, at 5% C0 2 , in DMEM containing 10% FBS. Cultures were then incubated with ABI4 2 (10 gM) or its vehicle for 3 h in the presence or absence of SP-233 (1 pM). To 20 assess mitochondrial uptake of ABi3 1 2 , a co-localization study was performed using an Anti-OxPhos Complex II 70-kDa subunit mouse monoclonal antibody raised against complex II of the mitochondrial respiratory chain (Molecular Probes, Eugene, OR) and a rabbit polyclonal antibody raised against amino acid residues 33-42 of ABI-4 2 (Signet Laboratories, Dedham, MA). Neuroblastoma 25 cells were washed with phosphate-buffered saline (PBS), fixed with methanol at -20'C, and rinsed with PBS. Cells were then blocked with PBS containing 10% donkey serum for 30 min and then incubated for 24 h at 4'C with the antibody raised against complex 11 (1:200 in PBS containing 1.5% donkey serum and 0.01% Triton X100). Cells were then washed with PBS and incubated with a 30 donkey anti-mouse rhodamine-labeled secondary antibody (1:200; Jackson IrnmunoResearch, West Grove, PA) for 2 h at room temperature. The same sequential steps were then followed using the antibody raised against amino acids 33-42 of ABI-4 2 (1:500) and a donkey-anti-rabbit secondary antibody labeled with the fluorescent marker Alexa Fluor@ 488 (Molecular Probes, 42 WO 2006/107902 PCT/US2006/012380 Eugene, OR). Coverslips were mounted with an aqueous mounting medium containing 4',6-diamidino-2-phenylindole-2-hydrochloride (DAPI; Vector Laboratories, Burlingame, CA). Confocal images were acquired using an Olympus Fluoview BX61 Laser Scanning microscope. 5 6. Statistical analysis All results are expressed as mean ± SD. Comparisons between groups were carried out using an Analysis of Variance (ANOVA) followed by Dunnett's test. P values <0.05 were accepted as significant. 10 B. Results 1. Effect of SP-233 on CCCP- or CsA-induced changes in mitochondrial respiration First, the effects of SP-233 at concentrations ranging from 1 fM to 100 15 pM on mitochondrial respiration were assessed by monitoring the evolution of MRC (Fig. 6). Increasing concentrations of SP-233 resulted in a progressive decrease in the MRC. At concentrations as low as 1 nM, SP-233 induced a significant decrease in the MRC of rat brain mitochondria, as compared to the control group (p<0.001; Fig. 6b). Concentrations of SP-233 at or above 10 pM, 20 induced a 50% decrease in the MRC. CCCP uncouples oxidative phosphorylation and increases 02 consumption. As shown in Figure 7a, 1 tM CCCP increases 02 consumption in rat brain mitochondria to 150% of the basal value (p<0.01). Concentrations of SP-233 ranging from 1-1000 pM completely abolished this effect (p<0.001 for 25 all), and the inhibition of CCCP-induced uncoupling in the presence of all of these SP-233 concentrations was associated with a decrease in 02 consumption values to 60-65% of the basal level. Hypoxia was induced by adding 1 ptM CsA to the incubation medium bathing the mitochondria (Zini et al. 1996). SP-233 did not counteract the 30 decrease in the MRC induced by CsA. On the contrary, it amplified this effect in a concentration-dependent manner (Fig. 7b). 43 WO 2006/107902 PCT/US2006/012380 2. Effects of SP-233 on changes in mitochondrial respiration induced by fresh and aged A01- 42 Addition of AB1- 42 to isolated mitochondria significantly decreased the MRC, even when present at concentrations of 0.1 pM (Fig. 8). This effect was 5 more pronounced with the fresh amyloid peptide than with the aged fonr; the inhibitory effect of the former was approximately 10% greater. It was hypothesize that the non-aggregated form of AB1- 42 penetrates into the mitochondria to a greater extent than the aged, aggregated form of the peptide. As shown in Figure 9a, addition of fresh AB1.
42 to isolated mitochondria resulted 10 in a decrease in the MRC to 71% of the control values, and this decrease was partially reversed by SP-233. At the lowest concentration of SP-233 tested (1 pM), the MRC was restored to approximately 39% of the control value. The MRC was significantly increased in comparison to the value obtained with ABI1 42 alone (38.56 : 0.34 vs. 28.93 ± 1.75, p<0.001). Aged AB1- 42 reduced the MRC 15 by 51% compared to the control, but SP-233 did not significantly affect this aged
AB
1
-
42 -induced change in the MRC (Fig. 9b). 3. Effect of SP-233 on AB1-42-induced toxicity on SK-N-AS human neuroblastoma cells 20 Figure 10 shows the effect of SP-23 3 on AB 1
-
42 -induced neurotoxicity in SK-N-AS cells. In the presence of all three AB1- 42 concentrations tested, addition of 1 [tM SP-233 resulted in a significant increase in cell viability. SP 233 decreased neurotoxicity induced by 0.1, 1, and 10iM AB1.
42 , by 19% (p<0.01, compared to AB1- 42 alone), 26% (p<0.01) and 28% (p<0.01), 25 respectively. 4. Effect of SP-233 on A131- 42 entry into the mitochondria of SK-N-AS cells Figure 11 shows representative images of the DAPI staining (al, b 1 and cl), the immunofluorescent labeling of AB1.
42 (a2, b2 and c2), and the 30 immunofluorescent labeling of the complex II 70-kDa subunit (a3, b3 and c3) in SK-N-AS human neuroblastoma cells. Merged images are shown in Figure a4, b4, and c4. Neuroblastoma cells treated with ABI- 42 displayed strong AB 1
.
42 immunoreactivity (Fig. 1 1b2) that co-localized with labeling of complex II of the mitochondrial respiratory chain (Fig. 11b4), providing evidence that AB1- 42 44 WO 2006/107902 PCT/US2006/012380 entered, and was present inside, the mitochondria. Afi..42 immunoreactivity was abrogated in the presence of SP-233 (Fig. 11c2), indicating that SP-233 blocked the entry of AB1- 42 into the cell and the mitochondria. 5 5. Neuroprotective effect of SP-233 against inhibitors of the mitochondrial complexes in SK-N-AS cells SP-233 did not display any neuroprotective effect against the inhibitors of complexes I, II, and III of the mitochondria respiratory chain (Fig. 12 a, b, and c). At concentrations of 1 pM, SP-233 significantly protected against rotenone 10 and 100 pM SP-233 significantly protected against myxoyhiazol (p<0.05 for both). Although this protective effect was significant, in both cases the magnitude of the effect was small. In contrast, SP-233 exerted a pronounced beneficial effect against toxicity induced by KCN, a complex IV inhibitor, and oligomycin, a complex V inhibitor (Fig. 12d and 12e). Low concentrations of 15 SP-233 (1, 3, and 10 piM) were active against KCN; whereas, high doses (30 and 100 pM) offered no beneficial effect. The protective effect of SP-233 against oligomycin was dose-dependent, although 10 ptM SP-233 did not demonstrate statistically significant neuroprotection. These data demonstrate that SP-233 protects SK-N-AS cells against inhibition of complexes IV and V. 20 6. Neuroprotective effect of SP-233 on PAO and FCCP in SK-N-AS cells Adenine nucleotide translocase (ANT) is a channel protein located in the inner membrane of the mitochondria that, under physiological conditions, exports ATP and imports ADP with a 1:1 ratio. The inhibition of ANT by PAO 25 promotes the opening of the permeability transition pore, which leads to apoptosis. One micro molar SP-233 reduced the toxic effect of PAO on SK-N AS neuronal cells by 25% (Fig. 13, p<0.01). Concentrations of SP-233 above 1 ptM were not associated with any neuroprotective effects. In addition, SP-233 exerted a small, but significant (p<0.01), effect on FCCP-induced uncoupling of 30 the respiratory chain when administered at the concentration of 100 pM (Fig. 14). 45 WO 2006/107902 PCT/US2006/012380 C. Discussion AD is clinically characterized by a progressive impairment of cognitive processes and memory loss. Early on, this "mnesic" aspect of the disease was related to the degeneration of central cholinergic pathways, as reflected by 5 decreases in synaptic concentrations of acetylcholine (ACh). Thus, drug research has focused on restoring the ACh levels in the brain, and this has led to the development of the acetylcholinesterase inhibitors (AChEIs). Although these drugs are invaluable for AD patients and their caregivers, AchEIs are symptomatic drugs that only slow down the progression of the disease for a 10 limited period of time without stopping it (Tariot and Winblad, 2001; Waldemar et al. 2001; Grossberg et al. 2004). Even though memantine, an N-methyl-D aspartate (NMDA) receptor antagonist, has recently been approved for treating moderately to severe AD (Livingston and Katona 2004), there is an urgent need for new drugs and new therapeutic strategies that target the etiological causes of 15 the AD. The etiology of AD is well documented for the familial, early-onset form of the disease, which involves a mutation of the APP (presenilin- 1 or presenilin 2) gene. In contrast, the cause of the late-onset sporadic form of AD, which represents about 95% of all AD cases, remains to be established. Many theories 20 have emerged, and among these is the proposal that an energetic failure due to mitochondrial impairment and oxidative damage may be at the origin of AD (Schulz et al. 1997; Beal, 2000). This mitochondrial dysfunction theory, together with the recent finding that the spirostenol derivative, SP-233, can protect neuronal PC 12 cells against AB1- 42 -induced neurotoxicity (Lecanu et al. 25 2004), led to the examination of whether SP-233 is capable of restoring the function of isolated mitochondria exposed to A1- 42 . The results provided herein demonstrate that SP-233 can protect mitochondrial functions against the toxic effects of ABI- 42 , both in isolated rat brain mitochondria and in human neuroblastoma cells. These observations suggest that 30 SP-233 has the potential to influence basic mechanisms that are associated with AB-induced neurotoxicity and have been implicated in the pathogenesis of AD. The effect of AB on mitochondrial function has been extensively investigated during the past ten years, and the data generated by these studies indicates that various effects of the peptide could lead to mitochondrial 46 WO 2006/107902 PCT/US2006/012380 dysfunction. A-BI 42 and the fragment AB 2 5- 35 have been shown to inhibit respiration and the activities of key enzymes such as succinate dehydrogenase, a-ketoglutarate dehydrogenase, pyruvate dehydrogenase, and cytochrome oxidase, in neuronal mitochondria (Kaneko et al. 1995; Casley et al. 2002a). 5 Inhibition of the respiratory chain complexes has also been reported in neuronal mitochondria exposed to AB 25
.
35 (Pereira et al. 1999; Canevari et al. 1999; Casley et .al. 2002b), and this same peptide fragment promoted pore-opening that is associated with the MPT (Moreira et al. 2001; Moreira et al. 2002; Bachurin et al. 2003). In addition, the results presented herein revealed that ABI 42 inhibited 10 mitochondrial respiration of rat brain mitochondria, as revealed by a decrease in the MRC. Moreover, this inhibition occurred in response to ABI- 42 concentrations as low as 0.1 pM, with both freshly prepared and aged forms of the peptide. It is likely that the inhibitory effect was more pronounced with the fresh form since the polymeric fonns of ABI- 42 would traverse mitochondrial 15 membranes to a lesser extent than the monomeric form or oligomeric forms such as ADDLs. These latter forms are more likely to exert their detrimental effects on the respiratory chain and are defacto more toxic. Also, the lack of protection imparted by SP-233 on mitochondria exposed to the aged/aggregated form of
ABI
42 might be due to the inability of SP-233 to bind the aggregated form of the 20 amyloid peptide in the same way that it binds the monomeric form. Interestingly, SP-233 was able to partially prevent the decrease in MRC induced by freshly prepared Af3 1 42 , confirming previous results showing a restorative effect of SP-233 on ATP synthesis in PC12 cells exposed to A1l- 42 (Lecanu et al. 2004). The finding that SP-233 is active at very low 25 concentrations suggests that its mechanism of action might be relatively specific. The data described herein also confirmed recent results showing that SP-233 protects neuronal cells against AB 1
-
42 neurotoxicity by binding to the monomeric form of the peptide and inhibiting the formation of the neurotoxic oligomeric ADDLs (Lecanu et al. 2004). 30 The confocal microscopy analysis performed on human neuroblastoma cells, in showing that AB 1 42 co-localized with complex II of the respiratory chain, indicated that ABI-42 is capable of traversing both the outer cell membrane and the mitochondrial membrane. When SP-233 and ABI- 42 were both present in the incubation medium, amyloid peptide labeling was abolished, and this 47 WO 2006/107902 PCT/US2006/012380 "scavenging" effect of SP-233 was accompanied by a partial restoration of the MRC. In addition, SP-233 partially prevented the neurotoxic effects of ABI 1
-
42 on the same human neuroblastoma cells. This finding is of particular interest in view of recent results showing that amyloid-deposits are present in the 5 mitochondria of cortical pyramidal neurons of post-mortem AD brain (Femandez-Vizarra et al. 2004). These histological features have been described as being a very early event in the progression of the disease, appearing before the formation of paired-helical filaments and leading to neuronal death. On this basis, the inactivation of AB1.
42 by SP-233, as described herein, may justify use 10 of SP-233 in the treatment of AD (Lecanu et al. 2004). After the binding and "scavenging" effects of SP-233 on AB 1
-
42 had been established, the possibility that a direct effect of SP-233 on mitochondria might result in an additive protective effect against AB1-42 was examined. In this regard, it has been shown that AB promotes the opening of MPT pores in brain 15 mitochondria, leading to functional impairment, and this affect is abolished by CsA (Moreira et al. 2001; Bachurin et al. 2003; Abramov et al. 2004). The experiments revealed that SP-233, like CsA, decreased the MRC. SP-233 also amplified the CsA's effects, suggesting that it might have CsA-like properties. That is, it might inhibit MPT pore opening, which could contribute to its 20 protective effect against AB 1
-
42 -induced mitochondrial dysfunction. This hypothesis is supported by SP-233's protective effect against PAO, a protein tyrosine phosphatase inhibitor known to promote the MPT (Korge et al., 2001). Thus, SP-233, at concentrations of 1 gM, restored neuronal cell viability by 25%; whereas, higher concentrations of SP-233 were not associated with a 25 protective effect. SP-233's effect on MPT-linked pore opening may occur via direct and/or indirect action (e.g., by allosteric modification after its insertion into mitochondrial membranes). SP-233 was also able to abolish CCCP-induced uncoupling of oxidative phosphorylation in isolated mitochondria and in neuroblastoma cells. It has been 30 shown that A31- 42 disrupts mitochondrial membrane structure (Kremer et al. 2001; Rodrigues et al. 2001) and that mitochondrial membrane fluidity may be altered in AD brain (Mecocci et al, 1996); both phenomena lead to mitochondrial uncoupling. Therefore, even though the "re-coupling" effect of SP-233 has not been fully clarified, it might contribute to the restoration of mitochondrial 48 WO 2006/107902 PCT/US2006/012380 function described herein. Moreover, a combination of the scavenging effect of SP-233 (presumably involving its modulation of MPT pores) and its re-coupling effect might account for SP-233's ability to counteract the effects of ABi 4 2 , at concentrations as low as 1 pM. 5 In an attempt to identify other targets of SP-233 in the mitochondrial respiratory chain, it was demonstrated that SP-233 is able to protect neuroblastoma cells against inhibitors of complexes I, III, IV, and V, but not against inhibitors of complex II (Fig. 15). The most pronounced effect was observed in complexes III and IV, although SP-233, at concentrations of 1 tM 10 and 100 tM, also exerted a small but significant neuroprotective effect against rotenone and myxothiazol-induced toxicity, respectively. The magnitude of the cell viability rescue against KCN and oligomycin compared to that against ABI 42 suggests that complexes IV and V are the main targets for the amyloid peptide induced impairment of mitochondrial functions. These findings confirm 15 previous results showing that the fragment AB 25
-
35 inhibits complex IV in isolated brain mitochondria (Canevari et al., 1999). However, in contrast to the data, the same authors reported that AB 25 -3 5 has no effect on the other complexes of the respiratory chain. This apparent discrepancy could be explained by differences in the amyloid species used, and it raises questions about the role of 20 AB 25
-
35 and ABi 42 in neuropathology. As AD is an incurable neurodegenerative disorder and as the existing treatments, most of which are based solely on the inhibition of the AChE, have serious limitations, there is an urgent need to develop more effective drugs. Here it is reported that the small molecule, SP-233, which has previously been 25 shown inhibits AB1-4 2 -induced neurotoxicity by blocking the formation of the ADDLs, protects brain mitochondria against the deleterious effects of AI- 42 exposure. The molecular mechanisms underlying SP-233's neuroprotective effects might be due, at least in part, to its "scavenging" of ABi- 4 2 , its "anti uncoupling" effect, its protective effect toward mitochondrial complexes IV and 30 V, and its ability to inhibit the opening of MPT pores. In conclusion, the data provided herein have confirmed and extended the previous findings showing that SP-233 possesses anti-amyloid properties, and they identify the mitochondria and the respiratory chain as direct targets for ABI 4 2 and SP-233. 49 WO 2006/107902 PCT/US2006/012380 Bibliography The publications listed below are incorporated by reference herein as though set forth in full. Abramov A.Y., Canevari L. and Duchen M. R. (2004) Beta-amyloid peptides 5 induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J. Neurosci. 24, 565-575. Bachurin S. 0., Shevtsova E. P., Kireeva E. G., Oxenkrug G. F. and Sablin S. 0. (2003) Mitochondria as a target for neurotoxins and neuroprotective agents. Ann. N.Y. Acad. Sci. 993, 334-344. 10 Beal M. F. (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative disease? Ann. Neurol. 31, 119-130. Beal M. F. (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23, 298-304. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H. and Yankner 15 B. A. (2002) Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33, 677-688. Canevari L., Clark J. B. and Bates T. E. (1999) f-amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS 20 Lett. 457, 131-134. Casley C. S., Canevari L., Land J. M., Clark J. B. and Sharpe M.A. (2002a) # Amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J. Neurochen. 80, 91-100. Casley C. S., Land J. M., Sharpe M. A., Clark J. B., Duchen M. R. and Canevari 25 L. (2002b) Beta-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol. Dis. 10, 258-267. Courtney C., Farrell D., Gray R. et al.; AD2000 Collaborative Group. (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363, 2105-2115. 30 Eckert G. P., Wood W. G. and Muller W. E. (2001) Effects of aging and f amyloid on the properties of brain synaptic and mitochondrial membranes. J Neural. Transin. 108, 1051-1064. Fernandez-Vizarra P., Fernandez A. P., Castro-Blanco S., Serrano J., Bentura M. L., Martinez-Murillo R., Martinez A. and Rodrigo J. (2004) Intra- and 50 WO 2006/107902 PCT/US2006/012380 extracellular AO and PHF in clinically evaluated cases of Alzheimer's disease. Histol. Histopathol. 19, 823-844. Grossberg G., Irwin P., Satlin A., Mesenbrink P. and Spiegel R. (2004) Rivastigmine in Alzheimer disease: efficacy over two years. Am. J Geriatr. 5 Psychiatiy 12, 420-43 1. Kaneko I., Yamada N., Sakuraba Y., Kamenosono M. and Tutumi S. (1995) Suppression of mitochondrial succinate dehydrogenase, a primary target of beta-amyloid, and its derivative recemized at Ser residue. J. Neurochem. 65, 2585-2593. 10 Kim S. H., Vlkolinsky R., Cairns N. and Lubec G. (2000) Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell. Mol. Life Sci. 57, 1810 1816. Kremer J. J., Sklansky D. J., Murphy R. M. (2001) Profile of changes in lipid 15 bilayer structure caused by beta-amyloid peptide. Biochemistry 40, 8563 8571. Kroemer G. and Reed J. C. (2000) Mitochondrial control of cell death. Nat. Med. 6, 513-519. Lecanu L., Yao W., Teper G. L., Yao Z. X., Greeson J. and Papadopoulos V. 20 (2004) dentification of naturally occurring spirostenols preventing beta amyloid-induced neurotoxicity. Steroids 69, 1-16. Livingston G. and Katona C. (2004) The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int. J. Geriatr. Psychiatry 19, 919. 25 Lowry 0. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the folin phenol reagent. J Biol. Chem. 93, 265-275. Lustbader J. W., Cirilli M., Lin C. et al. (2004) ABAD directly links AO to mitochondrial toxicity in Alzheimer's disease. Science 304, 448-452. Manfredi G. and Beal M. F. (2000) The role of mitochondria in the pathogenesis 30 of neurodegenerative diseases. Brain Pathol. 10, 462-472. Mecocci P., Cherubini A., Beal M. F., Cecchetti R., Chionne F., Polidori M. C., Romano G. and Senin U. (1996) Altered mitochondrial membrane fluidity in AD brain. Neurosci. Lett. 207, 129-132. 51 WO 2006/107902 PCT/US2006/012380 Moreira P. I., Santos M. S., Moreno A. and Oliveira C. (2001) Amyloid beta peptide promotes penneability transition pore in brain mitochondria. Biosci. Rep. 21, 789-800. Moreira P. I., Santos M. S., Moreno A., Rego A. C. and Oliveira C. (2002) 5 Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J. Neurosci. Res. 69, 257-267. Pereira C., Santos M. S. and Oliveira C. (1999) Involvement of oxidative stress on the impairment of energy metabolism induced by Abeta peptides on PC12 cells: protection by antioxidants. Neurobiol. Dis. 6, 209-219. 10 Rodrigues C. M. P., Sola S., Brito M. A., Brondino C. D., Brites D. and Moura J. J. G. (2001) Amyloid -peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochen. Biophys. Res. Commun. 281, 468-474. Sergeant N., Wattez A., Galvan-Valencia M. et al (2003) Association of ATP 15 synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience 117, 293-303. Schulz J. B., Matthews R. T., Klockgether T., Dichgans J. and Beal M. F. (1997) The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Moi. Cell. Biochem. 174, 193-197. 20 Tariot P. and Winblad B. (2001) Galantamine, a novel treatment for Alzheimer's disease: a review of long-term benefits to patients and caregivers in Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (Iqbal K., Sisodia S. S. and Winblad B., eds.), pp. 705-723. John Wiley & Sons, Chichester. 25 Volicer L. and Crino P. B. (1990) Involvement of free radicals in dementia of the Alzheimer type: a hypothesis. Neurobiol. Aging 11, 567-571. Waldemar G., Winblad B., Engedal K., Soininen H., Verhey F., Wimo A., Wetterholm A. L., Zhang R., Haglund A. and Subbiah P. (2001) Benefits of donepezil on cognition, function and neuropsychiatric symptoms in patients 30 with mild and moderate Alzheimer's disease over one year, in Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics (Iqbal K., Sisodia S. S. and Winblad B., eds.), pp. 725-738. John Wiley & Sons, Chichester. 52 WO 2006/107902 PCT/US2006/012380 Zini R., Simon N., Morin C., d'Athis P. and Tillement J. P. (1996) Inhibition of rat cerebral mitochondrial respiration by cyclosporins A, D, and G and restoration with trimetazidine. C. R. Acad Sci. III. 319, 1087-1092. 5 All publications, patents and patent applications are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled 10 in the art that the invention is susceptible to additional embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention. 53
Claims (31)
1. A therapeutic method comprising administering to a mammal afflicted with or threatened by, a mitochondrial disorder that is not a neuropathology of 5 the central nervous system comprising administering to said mammal an effective amount of a compound of formula (I): R16 y R17 R12 R13 R11 O R2 R1 RI R8 R9 R14 R1 R3 R7 R4 R6 1 wherein each of R 1 , R 2 , R 4 , R 7 , RI 1 , R 1 2 , and R 1 5 , independently, is 10 hydrogen, (CI-C 8 )alkyl, that is optionally inserted with -NR'-, -0-, -S-, -SO-, S02-, -0-SO 2 -, -S0 2 -0-, -C(O)-, -C(0)-0-, -O-C(O)-, -C(O)-NR'- or -NR' C(O)-; hydroxy, N(R') 2 , carboxyl, oxo, or sulfonic acid, R3 is hydroxy, (C 1 Cs)alkoxy, (CI-C 22 )alkylCO 2 , or R'0 2 C(CH 2 ) 2 - 8 CO 2 -, wherein (CI-C 22 )alkyl or (CH2)2-3 can optionally comprise 1-2 CH=CH units, 1-2 OH, and/or 1-2 epoxy 15 substituents, toluene-4-sulfonyloxy or benzoyloxy; each of R 6 , Rs, R 9 , Rio, R 13 , R 1 4 , R 16 and R 17 , independently, is hydrogen, (CI-Cs)alkyl, hydroxyl(C 1 Cs)alkyl, (CI-Cs)alkoxy, or hydroxy; and X is 0, S, S(O) or N(R'), N(Ac) or N(toluene-4-sulfonyloxy); wherein each R' is individually H, (CI-C 8 )alkyl, phenyl or benzyl, or a 20 phannaceutically acceptable salt thereof.
2. The therapeutic method of claim 1 wherein RIO and R1 3 are CH 3 .
3. The therapeutic method of claims 1 or 2 wherein one or both of R 16 and 25 R 17 are CH 3 .
4. The therapeutic method of any one of claims 1-3 wherein R 1 , R 2 or R 12 are H or OH. 54 WO 2006/107902 PCT/US2006/012380
5. The therapeutic method of any one of claims 1-4 wherein R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , R 9 , R, 1 , R 12 , R 14 and Ri 5 are H.
6. The therapeutic method of any one of claims 1-5 wherein R3 is (C 1 5 C 2 2 )alkylCO 2 -, (CI-C 6 )alkylCO 2 -, or is OH.
7. The therapeutic method of any one of claims 1-6 wherein X is 0.
8. The therapeutic method of any one of claims 1-6 wherein X is NH. 10
9. A therapeutic method of treating a mitochondrial disorder in a subject afflicted with or threatened by said disorder, wherein said disorder is not a neuropathology of the central nervous system, comprising administering to the subject an effective amount of a compound of formula (II): CH3 X CH R12 R13 RR11 0O R2 UR 0 8 R15 Rg R14 R3 Ry 15 R4 R6 (11) wherein each of R 1 , R 2 , R 4 , R 7 , RuI, R 1 2 , and R 15 , independently, is hydrogen, (C 1 -Cs)alkyl, hydroxy, amino, carboxyl, oxo, sulfonic acid, or (C 1 Cs)alkyl that is optionally inserted with -NH-, -N((C 1 -Cs)alkyl)-, -0-, -S-, -SO-, -S02-, -O-SO 2 -, -S0 2 -0-, -C(O)-, -C(0)-0-, -O-C(O)-, -C(O)-NR'- or -NR' 20 C(O)-, wherein R' is H or (C1-Cs)alkyl; R3 is hydroxy, (C 1 -C 6 )alkylCO 2 -, HO 2 C(CH 2 ) 2 CO 2 -, toluene-4-sulfonyloxy or benzoyloxy; each of R 6 , R 8 , R9, RIO, R 1 3 , and R 14 , independently, is hydrogen, (CI-Cs)alkyl, hydroxyl(CI-Cs)alkyl, (CI-Cs)alkoxy or hydroxy; and X is 0, N(H), N(Ac) or N(toluene-4 sulfonyloxy), or a pharmaceutically acceptable salt thereof 25
10. The method of claim 9 wherein R 3 is OH or (C 1 -C 6 )alkylCO 2 -.
11. The method of claim 9 or 10 wherein X is 0. 55 WO 2006/107902 PCT/US2006/012380
12. The method of claim 9 or 10 wherein X is NH.
13. The method of any one of claims 9-12 wherein RIO and R 13 are CH 3 . 5
14. The method of any one of claims 9-13 wherein R 1 , R 2 or R 12 are OH.
15. The method of any one of claims 9-15 wherein R 1 , R 2 , R 4 , R 6 , R 7 , R 8 , R 9 , R 11 , R 1 2 , R 14 and R 15 are H. 10
16. The method of any one of claims 1 or 9 wherein the compound is selected from the group consisting of (20a)-25 -methyl-(22R,26) azacyclofurost-5-en-3 -ol, (20 )-25 -methyl-N-acetyl-(22R,26)-azacyclofurost 5-en-34-ol, (22R,25 )-(20a)-spirost-5-en-(2a,34)-diol, (20a)-25 -methyl-N paratoluenesulfonyl-(22R,26)-azacyclofurost-5-en-3 -yl paratoluenesulfonate, 15 (22R,254)-(20a)-(14a,20a)-spirost-5-en-(3 ,12 )-diol, (22R,25S)-(204)-spirost 5-en-3 -ol, (22R,25 )-(20a)-spirost-5-en-3p-yl benzoate, (22S,25S)-(20S) spirost-5-en-3p-yl hexanoate, (22R,254)-(20a)-spirost-5-en-(14,34)-diol, (22R,25S)-(20a)-spirost-5-en-3 -ol, (22R,25S)-(20a)-spirost-5-en-3 -yl succinate, and (20a)-25S-methyl-N-acetyl-(22S,26)-azacyclofurost-5-en-3p-yl 20 propanoate.
17. The method of claim 16 wherein the compound is (22S,25S)-(20S) spirost-5-en-3 -yl hexanoate. 25
18. The method of claims 1 or 9 wherein the compound is administered in a dosage form comprising a therapeutically effective amount of the compound.
19. The method of claim 18 wherein the dosage form is selected from the group consisting of a tablet, a soft gelatin capsule, a hard gelatin capsule, a 30 suspension tablet, an effervescent tablet, a powder, an effervescent powder, a chewable tablet, a solution, a suspension, an emulsion, a cream, a gel, a patch, and a suppository. 56 WO 2006/107902 PCT/US2006/012380
20. The method of claim 19 wherein the dosage form further comprises a pharmaceutically acceptable excipient.
21. The method of claim 20 wherein the phannaceutically acceptable 5 excipient comprises a binder, a disintegrant, a filler, a surfactant, a solubilizer, a stabilizer, a lubricant, a wetting agent, a diluent, an anti-adherent, a glidant, or a pharmaceutically compatible carrier.
22. The method of any one of claims 1-21 wherein the mitochondrial 10 disorder is a mitochondrial disease.
23. The method of any one of claims 1-21 wherein the mitochondrial disorder is a myopathy. 15
24. The method of claim 23 wherein the myopathy is cardiomyopathy.
25. The method of any one of claims 1-21 wherein the mitochondrial disorder is a tubulopathy. 20
26. The method of any one of claims 1-21 wherein the mitochondrial disorder is due to compartment syndrome or crushed muscle syndrome.
27. The method of any one of claims 1-21 wherein the neuropathology of the central nervous system is selected from the group consisting of global and focal 25 ischemic or hemorrhagic stroke, head trauma, spinal cord injury, hypoxia induced nerve cell damage, nerve cell damage caused by cardiac arrest or neonatal distress, epilepsy, anxiety, spinal cord lesion, ALS, Alzheimer's Disease, Huntington's disease, and Parkinson's disease. 30
28. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of formulas (I) or (II) in combination with a pharmaceutically acceptable excipient.
29. Use of a compound of formula (I): 57 WO 2006/107902 PCT/US2006/012380 R16 X R17 R12 R13 R2 R1 R, R8 R9 R14 R15 R3 Ry R4 R() wherein each of R 1 , R 2 , R 4 , R 7 , R, 1 , R 1 2 , and R 15 , independently, is hydrogen, (C1-Cs)alkyl, that is optionally inserted with -NR'-, -0-, -S-, -SO-, 5 SO 2 -, -O-SO2-, -S0 2 -0-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-NR'- or -NR' C(O)-; hydroxy, N(R') 2 , carboxyl, oxo, or sulfonic acid, R 3 is hydroxy, (C 1 Cs)alkoxy, (CI-C 22 )alkylCO 2 , or R'0 2 C(CH 2 ) 2 - 8 CO 2 -, wherein (CI-C 22 )alkyl or (CH2)2-3 can optionally comprise 1-2 CH=CH units, 1-2 OH, and/or 1-2 epoxy substituents, toluene-4-sulfonyloxy or benzoyloxy; each of R 6 , R 8 , R 9 , Rio, R 13 , 10 R 1 4 , R 16 and R 17 , independently, is hydrogen, (C1-Cs)alkyl, hydroxyl(C 1 C 8 )alkyl, (CI-Cs)alkoxy, or hydroxy; and X is 0, S, S(O) or N(R'), N(Ac) or N(toluene-4-sulfonyloxy); wherein each R' is individually H, (CI-Cs)alkyl, phenyl or benzyl, or a pharmaceutically acceptable salt thereof 15 to prepare a medicament for treating a mitochondrial disease or disorder that is not a neuropathology of the central nervous system.
30. Use of a compound of formula (II): R12 R 1 3 R, Rx, R R2 RI 8 R15 R9 R14 R3 YR1H Ry R R4 R6 (H1) 20 wherein each of R1, R2, R4, R7, RI , R12, and R15, independently, is hydrogen, (C1-Cs)alkyl, hydroxy, amino, carboxyl, oxo, sulfonic acid, or (C1 C 8 )alkyl that is optionally inserted with -NH-, -N((CI-Cs)alkyl)-, -O-, -S-, -so-, -SO 2 -, -O-SO 2 -, -S0 2 -0-, -C(O)-, -C(O)-O-, -O-C(O)-, -C(O)-NR'- or -NR' C(O)-, wherein R' is H or (CI-Cs)alkyl; R 3 is hydroxy, (C 1 -C 6 )alkylCO 2 -, 58 WO 2006/107902 PCT/US2006/012380 HO 2 C(CH 2 ) 2 CO 2 -, toluene-4-sulfonyloxy or benzoyloxy; each of R 6 , R 8 , R 9 , Rio, R 13 , and R 14 , independently, is hydrogen, (C 1 -Cs)alkyl, hydroxyl(C1-Cs)alkyl, (CI-Cs)alkoxy or hydroxy; and X is 0, N(H), N(Ac) or N(toluene-4 sulfonyloxy), or a phannaceutically acceptable salt thereof 5 to prepare a medicament for treating a mitochondrial disease or disorder that is not a neuropathology of the central nervous system.
31. The use of claim 29 or 30, wherein the medicament includes a physiologically acceptable carrier. 10 59
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66722905P | 2005-04-01 | 2005-04-01 | |
US60/667,229 | 2005-04-01 | ||
US69751805P | 2005-07-08 | 2005-07-08 | |
US60/697,518 | 2005-07-08 | ||
PCT/US2006/012380 WO2006107902A2 (en) | 2005-04-01 | 2006-03-31 | Use of spirostenols to treat mitochondrial disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2006231451A1 true AU2006231451A1 (en) | 2006-10-12 |
Family
ID=36676082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006231451A Abandoned AU2006231451A1 (en) | 2005-04-01 | 2006-03-31 | Use of spirostenols to treat mitochondrial disorders |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1893219A2 (en) |
JP (1) | JP2008534623A (en) |
AU (1) | AU2006231451A1 (en) |
CA (1) | CA2603127A1 (en) |
WO (1) | WO2006107902A2 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4680289A (en) * | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
WO2003022287A1 (en) * | 2001-08-24 | 2003-03-20 | Jilin Tianyao Science And Technology Co. Ltd. | USE OF 3β-HYDROXY-5-SPIROSTENE AS DRUGS FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES OR CONDITIONS FOR INHIBITION OF TUMORS AND DECREASING OF BLOOD LIPIDS |
AU2003218180B2 (en) * | 2002-03-15 | 2008-03-20 | Georgetown University | Neuroprotective spirostenol pharmaceutical compositions |
WO2003086411A1 (en) * | 2002-04-15 | 2003-10-23 | Chengdu Di'ao Pharmaceutical Group Co., Ltd. | Compounds and preparation methods of carboxylate and monoester succinate derivative of diosgenin |
CN1187055C (en) * | 2002-06-21 | 2005-02-02 | 成都地奥制药集团有限公司 | Medicine composition for treating myocardial ischemia, angina pectoris and cardiac infarction |
CN1224628C (en) * | 2003-11-29 | 2005-10-26 | 刘良 | Preparation of solanine sulfurate and its use in medicine |
CA2584333A1 (en) * | 2004-10-14 | 2006-04-27 | Georgetown University | Neuroprotective spirostenol pharmaceutical compositions |
-
2006
- 2006-03-31 JP JP2008504515A patent/JP2008534623A/en active Pending
- 2006-03-31 WO PCT/US2006/012380 patent/WO2006107902A2/en active Application Filing
- 2006-03-31 CA CA002603127A patent/CA2603127A1/en not_active Abandoned
- 2006-03-31 AU AU2006231451A patent/AU2006231451A1/en not_active Abandoned
- 2006-03-31 EP EP06740438A patent/EP1893219A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2006107902A2 (en) | 2006-10-12 |
WO2006107902A8 (en) | 2008-01-24 |
WO2006107902A9 (en) | 2007-01-18 |
WO2006107902A3 (en) | 2006-11-30 |
JP2008534623A (en) | 2008-08-28 |
CA2603127A1 (en) | 2006-10-12 |
EP1893219A2 (en) | 2008-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5393151B2 (en) | Liposome compositions containing antihistamines and corticosteroids and their use for the manufacture of a medicament for the treatment of rhinitis and related diseases | |
EP2978419B1 (en) | Compositions for improving cell viability and methods of use thereof | |
US20070197484A1 (en) | Method of treating disorder related to high cholesterol concentration | |
US20040014734A1 (en) | Farnesoid X-activated receptor agonists | |
US20030153541A1 (en) | Novel anticholesterol compositions and method for using same | |
JP2006525226A (en) | Therapeutic formulations for the treatment of β-amyloid related diseases | |
CA2564353A1 (en) | Galantamine salts, method of producing it and nasal composition thereof | |
SG178000A1 (en) | Methods and combination therapies for treating alzheimer's disease | |
CA2466033A1 (en) | Method of treating disorder related to high cholesterol concentration | |
AU2003218180B2 (en) | Neuroprotective spirostenol pharmaceutical compositions | |
JPH09511506A (en) | Permanent ionic derivatives of steroid hormones and their antagonists | |
JP2018076332A (en) | EFFECTIVE AMOUNTS OF (3aR)-1,3a,8-TRIMETHYL-1,2,3,3a,8,8a-HEXAHYDROPYRROLO[2,3-b]INDOL-5-YL PHENYLCARBAMATE AND METHODS OF USING THE SAME | |
US7078396B2 (en) | Method of treating disorder related to high cholesterol concentration | |
Tillement et al. | The spirostenol (22R, 25R)-20α-spirost-5-en-3β-yl hexanoate blocks mitochondrial uptake of Aβ in neuronal cells and prevents Aβ-induced impairment of mitochondrial function | |
AU2006231451A1 (en) | Use of spirostenols to treat mitochondrial disorders | |
WO2000041700A1 (en) | Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders | |
EP2440211B1 (en) | Use of telocinobufagin as an analgesic in the treatment of acute and chronic pains; pharmaceutical composition containing telocinobufagin and its use | |
US6608080B1 (en) | Morphan derivatives or salts thereof and medicinal compositions containing the same | |
US11124479B2 (en) | Oligopyrroles as antagonists of islet amyloid polypeptide oligomerization | |
AU2002356919B2 (en) | Method of treating disorder related to high cholesterol concentration | |
CN101227911A (en) | Use of spirostenols to treat mitochondrial disorders | |
WO2024103012A1 (en) | Polycyclic compounds for use in neurodegenerative conditions | |
US20210030714A1 (en) | Compounds for use in the treatment of brain diseases | |
KR101198201B1 (en) | Method and composition for treating rhinitis | |
AU2002356919A1 (en) | Method of treating disorder related to high cholesterol concentration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |